



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C07D 413/12, 265/30, A61K 31/535, 31/44		A1	(11) International Publication Number: <b>WO 98/39329</b>  (43) International Publication Date: 11 September 1998 (11.09.98)
<p>(21) International Application Number: PCT/US98/04299</p> <p>(22) International Filing Date: 4 March 1998 (04.03.98)</p> <p>(30) Priority Data: Not furnished 4 March 1997 (04.03.97) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard - 40E, St. Louis, MO 63167 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): HEINTZ, Robert, M. [US/US]; 603 Nancy Place, Ballwin, MO 63021 (US). GETMAN, Daniel, P. [US/US]; 66 Sunny Hill Court, Chesterfield, MO 63017 (US). McDONALD, Joseph, J. [US/US]; 1036 Johanna Drive, Ballwin, MO 63021 (US). DeCRESCENZO, Gary, A. [US/US]; 7345 Spruce Hill Court, St. Charles, MO 63167 (US). HOWARD, Susan, C. [US/US]; 35 Worthy Court, Fenton, MO 63026 (US). ABBAS, S., Zaheer</p> <p>(74) Agents: GAMSON, Edward, P. et al.; Welsh &amp; Katz, Ltd., 22nd floor, 120 South Riverside Plaza, Chicago, IL 60606 (US).</p>		<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: AMIDOAROMATIC RING SULFONAMIDE HYDROXAMIC ACID COMPOUNDS</p> <p>(57) Abstract</p> <p>An amidoaromatic ring sulfonamide hydroxamic acid compound that <i>inter alia</i> inhibits matrix metalloprotease activity is disclosed, as are a treatment process that comprises administering a contemplated amidoaromatic ring sulfonamide hydroxamic acid compound in an MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AMIDOAROMATIC RING SULFONAMIDE  
HYDROXAMIC ACID COMPOUNDS

Description

5 Technical Field

This invention is directed to proteinase (protease) inhibitors, and more particularly to amidoaromatic ring sulfonamide hydroxamic acid compounds that, *inter alia*, exhibit activity as 10 inhibitors for matrix metalloproteinases, compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the preparation of proteinase inhibitors and processes for treating pathological conditions associated with 15 pathological matrix metalloproteinase activity.

Background of the Invention

Connective tissue, extracellular matrix constituents and basement membranes are required 20 components of all mammals. These components are the biological materials that provide rigidity, differentiation, attachments and, in some cases, elasticity to biological systems including human beings and other mammals. Connective tissues components 25 include, for example, collagen, elastin, proteoglycans, fibronectin and laminin. These biochemicals makeup, or are components of structures, such as skin, bone, teeth, tendon, cartilage, basement membrane, blood vessels, cornea and vitreous humor.

30 Under normal conditions, connective tissue turnover and/or repair processes are controlled and in

equilibrium. The loss of this balance for whatever reason leads to a number of disease states. Inhibition of the enzymes responsible loss of equilibrium provides a control mechanism for this tissue decomposition and, 5 therefore, a treatment for these diseases.

Degradation of connective tissue or connective tissue components is carried out by the action of proteinase enzymes released from resident tissue cells and/or invading inflammatory or tumor 10 cells. A major class of enzymes involved in this function are the zinc metalloproteinases (metalloproteases).

The metalloprotease enzymes are divided into classes with some members having several different 15 names in common use. Examples are: collagenase I (MMP-1, fibroblast collagenase; EC 3.4.24.3); collagenase II (MMP-8, neutrophil collagenase; EC 3.4.24.34), collagenase III (MMP-13), stromelysin 1 (MMP-3; EC 3.4.24.17), stromelysin 2 (MMP-10; EC 20 3.4.24.22), proteoglycanase, matrilysin (MMP-7), gelatinase A (MMP-2, 72kDa gelatinase, basement membrane collagenase; EC 3.4.24.24), gelatinase B (MMP-9, 92kDa gelatinase; EC 3.4.24.35), stromelysin 3 (MMP-11), metalloelastase (MMP-12, HME, human 25 macrophage elastase) and membrane MMP (MMP-14). MMP is an abbreviation or acronym representing the term Matrix Metalloprotease with the attached numerals providing differentiation between specific members of the MMP group.

30 The uncontrolled breakdown of connective tissue by metalloproteases is a feature of many

pathological conditions. Examples include rheumatoid arthritis, osteoarthritis, septic arthritis; corneal, epidermal or gastric ulceration; tumor metastasis, invasion or angiogenesis; periodontal disease;

5 proteinuria; Alzheimer's Disease; coronary thrombosis and bone disease. Defective injury repair processes also occur. This can produce improper wound healing leading to weak repairs, adhesions and scarring. These latter defects can lead to disfigurement and/or

10 permanent disabilities as with post-surgical adhesions.

Matrix metalloproteases are also involved in the biosynthesis of tumor necrosis factor (TNF) and inhibition of the production or action of TNF and related compounds is an important clinical disease

15 treatment mechanism. TNF- $\alpha$ , for example, is a cytokine that at present is thought to be produced initially as a 28 kD cell-associated molecule. It is released as an active, 17 kD form that can mediate a large integer of deleterious effects *in vitro* and *in vivo*. For example,

20 TNF can cause and/or contribute to the effects of inflammation, rheumatoid arthritis, autoimmune disease, multiple sclerosis, graft rejection, fibrotic disease, cancer, infectious diseases, malaria, mycobacterial infection, meningitis, fever, psoriasis,

25 cardiovascular/pulmonary effects such as post-ischemic reperfusion injury, congestive heart failure, hemorrhage, coagulation, hyperoxic alveolar injury, radiation damage and acute phase responses like those seen with infections and sepsis and during shock such

30 as septic shock and hemodynamic shock. Chronic release

of active TNF can cause cachexia and anorexia. TNF can be lethal.

TNF- $\alpha$  convertase is a metalloproteinase involved in the formation of active TNF- $\alpha$ . Inhibition 5 of TNF- $\alpha$  convertase inhibits production of active TNF- $\alpha$ . Compounds that inhibit both MMPs activity have been disclosed in WIPO International Publication Nos. WO 94/24140, WO 94/02466 and WO 97/20824. There 10 remains a need for effective MMP and TNF- $\alpha$  convertase inhibiting agents. Compounds that inhibit MMPs such as collagenase, stromelysin and gelatinase have been shown to inhibit the release of TNF (Gearing et al. *Nature* 376, 555-557 (1994), McGeehan et al., *Nature* 376, 558-561 (1994)).

15 MMPs are involved in other biochemical processes in mammals as well. Included is the control of ovulation, post-partum uterine involution, possibly implantation, cleavage of APP ( $\beta$ -Amyloid Precursor Protein) to the amyloid plaque and inactivation of 20  $\alpha_1$ -protease inhibitor ( $\alpha_1$ -PI). Inhibition of these metalloproteases permits the control of fertility and the treatment or prevention of Alzheimers Disease. In addition, increasing and maintaining the levels of an endogenous or administered serine protease inhibitor 25 drug or biochemical such as  $\alpha_1$ -PI supports the treatment and prevention of diseases such as emphysema, pulmonary diseases, inflammatory diseases and diseases of aging such as loss of skin or organ stretch and resiliency.

Inhibition of selected MMPs can also be desirable in other instances. Treatment of cancer and/or inhibition of metastasis and/or inhibition of angiogenesis are examples of approaches to the

5 treatment of diseases wherein the selective inhibition of stromelysin (MMP-3), gelatinase (MMP-2), or collagenase III (MMP-13) are the relatively most important enzyme or enzymes to inhibit especially when compared with collagenase I (MMP-1). A drug that does

10 not inhibit collagenase I can have a superior therapeutic profile. Osteoarthritis, another prevalent disease wherein it is believed that cartilage degradation in inflamed joints is at least partially caused by MMP-13 released from cells such as stimulated

15 chondrocytes, may be best treated by administration of drugs one of whose modes of action is inhibition of MMP-13. See, for example, Mitchell et al., *J. Clin. Invest.*, 97:761-768 (1996) and Reboul et al., *J. Clin. Invest.*, 97:2011-2019 (1996).

20 Inhibitors of metalloproteases are known. Examples include natural biochemicals such as tissue inhibitor of metalloproteinase (TIMP),  $\alpha_2$ -macroglobulin and their analogs or derivatives. These are high molecular weight protein molecules that form inactive

25 complexes with metalloproteases. An integer of smaller peptide-like compounds that inhibit metalloproteases have been described. Mercaptoamide peptidyl derivatives have shown ACE inhibition *in vitro* and *in vivo*. Angiotensin converting enzyme (ACE) aids in the

30 production of angiotensin II, a potent pressor

substance in mammals and inhibition of this enzyme leads to the lowering of blood pressure.

Thiol group-containing amide or peptidyl amide-based metalloprotease (MMP) inhibitors are known 5 as is shown in, for example, WO95/12389, WO96/11209 and U.S. 4,595,700. Hydroxamate group-containing MMP inhibitors are disclosed in a number of published patent applications such as WO 95/29892, WO 97/24117, and EP 0 780 386 that disclose carbon back-boned compounds, and WO 90/05719, WO 93/20047, WO 10 95/09841 and WO 96/06074 that disclose hydroxamates that have a peptidyl back-bones or peptidomimetic back-bones, as does the article by Schwartz et al., *Progr. Med. Chem.*, 29:271-334 (1992) and those of Rasmussen et 15 al., *Pharmacol. Ther.*, 75(1): 69-75 (1997) and Denis et al., *Invest. New Drugs*, 15(3): 175-185 (1997).

One possible problem associated with known MMP inhibitors is that such compounds often exhibit the same or similar inhibitory effects against each of the 20 MMP enzymes. For example, the peptidomimetic hydroxamate known as batimastat is reported to exhibit IC<sub>50</sub> values of about 1 to about 20 nanomolar (nM) against each of MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9. Marimastat, another peptidomimetic hydroxamate was 25 reported to be another broad-spectrum MMP inhibitor with an enzyme inhibitory spectrum very similar to batimastat, except that marimastat exhibited an IC<sub>50</sub> value against MMP-3 of 230 nM. Rasmussen et al., *Pharmacol. Ther.*, 75(1): 69-75 (1997).

30 Meta analysis of data from Phase I/II studies using marimastat in patients with advanced, rapidly

progressive, treatment-refractory solid tumor cancers (colorectal, pancreatic, ovarian, prostate). indicated a dose-related reduction in the rise of cancer-specific antigens used as surrogate markers for biological 5 activity. The most common drug-related toxicity of marimastat in those clinical trials was musculoskeletal pain and stiffness, often commencing in the small joints in the hands, spreading to the arms and shoulder. A short dosing holiday of 1-3 weeks followed 10 by dosage reduction permits treatment to continue.

Rasmussen et al., *Pharmacol. Ther.*, 75(1): 69-75 (1997). It is thought that the lack of specificity of inhibitory effect among the MMPs may be the cause of that effect.

15 In view of the importance of hydroxamate MMP inhibitor compounds in the treatment of several diseases and the lack of enzyme specificity exhibited by two of the more potent drugs now in clinical trials, it would be a great benefit if hydroxamates of greater 20 enzyme specificity could be found. This would be particularly the case if the hydroxamate inhibitors exhibited limited inhibition of MMP-1 that is relatively ubiquitous and as yet not associated with any pathological condition, while exhibiting quite high 25 inhibitory activity against one or more of MMP-2, MMP-9 or MMP-13 that are associated with several pathological conditions. The disclosure that follows describes one family of hydroxamate MMP inhibitors that exhibit those desirable activities.

30


Brief Summary of the Invention

The present invention provides compounds and their pharmaceutically acceptable salts effective as inhibitors of matrix metalloprotease enzyme activity; the provision of such compositions that are effective for the inhibition of metalloproteases (MMPs) believed to be implicated in diseases and disorders involving uncontrolled breakdown of connective tissue. Exemplary diseases and disorders (pathological conditions) include, for example, rheumatoid arthritis, 10 osteoarthritis, septic arthritis, corneal, epidermal or gastric ulceration, snake bite, tumor metastasis, growth, invasion or angiogenesis, periodontal disease, proteinuria, Alzheimer's Disease, multiple sclerosis, coronary thrombosis and bone disease. Also 15 contemplated are the provision of processes for preparing such compositions; the provision of processes for treating pathological conditions associated with abnormal matrix metalloprotease activity. A contemplated process effective for treating such 20 pathological conditions acts by selective inhibition of metalloproteases associated with such conditions with minimal side effects resulting from inhibition of other proteases whose activity is necessary or desirable for normal body function.

25 Briefly, therefore, the present invention is directed to a compound of Formula I or a pharmaceutically acceptable acid or base addition salt of a compound of Formula I, as well as a pharmaceutical composition of a compound of Formula I or a 30 pharmaceutically acceptable acid or base addition salt of a compound of Formula I, and also a process for

treating conditions associated with pathological matrix metalloprotease activity comprising administering a matrix metalloprotease inhibitor in an effective dosage to a host suffering from such condition.

5 The present invention relates to a compound of Formula I:



wherein:

10 n is an integer zero, 1 or 2;

W is independently selected from the group consisting of -NR<sup>5</sup>COR<sup>6</sup>, -NR<sup>5</sup>S(O)<sub>z</sub>R<sup>7</sup> where z is zero, 1, or 2, -NR<sup>5</sup>COOR<sup>8</sup>, -NR<sup>5</sup>CONR<sup>8</sup>R<sup>9</sup> and -NR<sup>11</sup>R<sup>12</sup>,

15 R<sup>1</sup> is cycloalkylene, arylene or heteroarylene;

R<sup>2</sup> is selected from the group consisting of a hydrogen (hydrido), alkyl, aralkyl, heteroaralkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, alkylthioalkyl, hydroxycarbonylalkyl, aroylalkyl, and 20 heteroaroylalkyl group, -(CH<sub>2</sub>)<sub>x</sub>-NR<sup>11</sup>R<sup>12</sup>, or -(CH<sub>2</sub>)<sub>x</sub>-C(O)NR<sup>11</sup>R<sup>12</sup>, wherein x is an integer from zero to 6;

25 R<sup>3</sup> is selected from the group consisting of a hydrogen (hydrido), alkyl, aryl, aralkyl, thioalkyl, heteroaralkyl, heteroaryl, alkoxyalkoxyalkyl, trifluoromethylalkyl, alkoxy carbonylalkyl,

-10-

aralkoxycarbonylalkyl, hydroxycarbonylalkyl, alkoxyalkyl, heterocycloalkylalkyl, aryloxyalkyl, alkylthioalkyl, arylthioalkyl, heteroarylthioalkyl group, or a sulfoxide or sulfone of any of said thio-  
5 containing groups, a  $-(CH_2)_x-C(O)NR^{11}R^{12}$  group, wherein x is an integer from zero to 6, and a  $-(CH_2)_y-W$  group, wherein y is an integer from 1 to 6 and W is defined above;

10 or R<sup>2</sup> and R<sup>3</sup> together with the atom chain to which they are attached form a 3-8 membered ring;

R<sup>4</sup> is a hydrogen (hydrido) or C<sub>1</sub>-C<sub>4</sub> alkyl group;

15 R<sup>5</sup> is a hydrogen (hydrido) or C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>6</sup> is selected from the group consisting of a hydrogen (hydrido), cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, alkylthioalkyl group, and a  $-(CH_2)_x-NR^{11}R^{12}$  group wherein x is an integer from zero to 6. The aryl or heteroaryl groups of R<sup>6</sup> are optionally substituted (unsubstituted or substituted) with one or more substituents independently selected from the group consisting of a halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, nitro, cyano, hydroxy, carboxy, hydroxycarbonylalkyl,  $-(CH_2)_x-NR^{11}R^{12}$ , wherein x is an integer from zero to 6, trifluoromethyl, alkoxycarbonyl, aminocarbonyl, thio, alkylsulfonyl, carbonylamino, aminosulfonyl, alkylsulfonamino,

alkoxyalkyl, cycloalkyloxy, alkylthioalkyl or alkylthio;

5 a) or R<sup>5</sup> and R<sup>6</sup> together with the atom chain to which they are bonded form a 5- to 7-membered a cyclic amide or imide that is substituted or unsubstituted;

10 b) or R<sup>5</sup> and R<sup>7</sup> together with the atom chain to which they are bonded form a 5- to 7-membered a cyclic sulfonamide that is substituted or unsubstituted;

R<sup>7</sup> is selected from the group consisting of R<sup>6</sup> and alkyl;


15 R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of R<sup>6</sup> and alkyl, or R<sup>8</sup> and R<sup>9</sup> together with the depicted nitrogen atom form a 5- to 7-membered ring containing zero or one heteroatom that is oxygen, nitrogen or sulfur;

20 R<sup>11</sup> and R<sup>12</sup> are independently selected from the group consisting of a hydrogen (hydrido), alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, alkanoyl, aralkanoyl, and heteroaralkanoyl group, or R<sup>11</sup> and R<sup>12</sup> taken together form a 5 to 8-membered heterocyclo or heteroaryl ring; and

25 R<sup>13</sup> is a hydrogen (hydrido) or C<sub>1</sub>-C<sub>6</sub> alkyl group.

The present invention also relates to a compound of Formula II:

-12-



wherein:

m is an integer from 1 to 6;


5                   W, R1, R2 and R13 have the meanings described above;

R4 is a hydrogen (hydrido) or C1-C4 alkyl group, as before;

10                  or R4 and W of -(CH2)x-W together with the atom chain to which they are attached form a 4-8-membered ring.

Another particular embodiment of the invention relates to a compound of Formula III:


15



wherein R2, R3, R4, R6 and R13 are as described above.


20                  One particular embodiment of the invention relates to a compound of Formula IV:

-13-




wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>8</sup> and R<sup>13</sup> are as defined previously.

5 A further particular embodiment of the invention relates to a compound of Formula V:




10 wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>7</sup> and R<sup>13</sup> are as defined previously.

Yet another particular embodiment of the invention relates to a compound of Formula VI:



15 wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>8</sup>, R<sup>9</sup> and R<sup>13</sup> are as defined previously.

A still further particular embodiment of the invention relates to a compound of Formula VII:



5


wherein:

n, W, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>13</sup> are as defined previously, and


R<sup>14</sup> is selected from the group consisting of  
 10 a hydrido, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, substituted aryl,  
 arylalkyl, substituted arylalkyl, alkanoyl,  
 cycloalkylcarbonyl, aralkanoyl, aroyl, and  
 heterocyclcarbonyl group. R<sup>14</sup> is preferably a  
 hydrido group, in which case a compound of formula VII  
 15 becomes a compound of formula I, or an acyl group such  
 as an alkanoyl, cycloalkylcarbonyl, aralkanoyl, aroyl,  
 and heterocyclcarbonyl group.

A contemplated compound contains an  
 20 asymmetric carbon atom at the alpha-position so that  
 enantiomeric, d and l or R and S, forms of each  
 compound exist. A particularly preferred  
 stereoconfiguration for a contemplated enantiomeric  
 compound is shown generically below in Formulas IA and  
 VIIA, wherein R<sup>3</sup> is hydrido and not depicted, and W, n,  
 25 the depicted R groups are as defined before.

-15-



IA



VIIA

In the above formulas, the dashed line represents a bond that extends beneath the plane of the page, whereas the solid wedge-shaped line represents a bond that extends above the plane of the page, as is usual in stereochemical depictions.

As utilized herein, the term "alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing from 1 to about 12, preferably from 1 to about 10, carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like. The term "alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to about 12 carbon atoms preferably from 2 to about 10 carbon atoms. Examples of suitable alkenyl radicals include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, decenyl and the like. The term "alkynyl", alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing from 2 to about 12 carbon atoms preferably from 2 to about 10 carbon atoms. Examples of alkynyl

radicals include ethynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, 3-butynyl, and the like.

The term "carbonyl", alone or in combination, means a  $-C(=O)-$  group wherein the remaining two bonds 5 (valences) can be independently substituted. The term "thiol" or "sulfhydryl", alone or in combination, means a  $-SH$  group. The term "thio" or "thia", alone or in combination, means a thiaether group; i.e., an ether group wherein the ether oxygen is replaced by a sulfur 10 atom.

The term "amino", alone or in combination, means an amine or  $-NH_2$  group whereas the term mono-substituted amino, alone or in combination, means a substituted amino  $-N(H)$  (substituent) group wherein one 15 hydrogen atom is replaced with a substituent, and disubstituted amino means a  $-N(\text{substituent})_2$  wherein two hydrogen atoms of the amino group are replaced with independently selected substituent groups. Amines, amino groups and amides are classes that can be 20 designated as primary ( $I^\circ$ ), secondary ( $II^\circ$ ) or tertiary ( $III^\circ$ ) or unsubstituted, mono-substituted or di-substituted depending on the degree of substitution of the amino nitrogen. Quaternary amine ( $IV^\circ$ ) means a 25 nitrogen with four substituents ( $-N^+(\text{substituent})_4$ ) that is positively charged and accompanied by a counter ion or N-oxide means one substituent is oxygen and the group is represented as ( $-N^+(\text{substituent})_3-O^-$ ), i.e., the charges are internally compensated.

The term "cyano", alone or in combination, 30 means a  $-C$ -triple bond- $N$  ( $-CN$ ) group. The term

"azido", alone or in combination, means a -N-double bond-N-double bond-N (-N=N=N) group.

The term "hydroxyl", alone or in combination, means a -OH group. The term "nitro", alone or in  
5 combination, means a -NO<sub>2</sub> group.

The term "azo", alone or in combination, means a -N=N- group wherein the bonds at the terminal positions are independently substituted. The term "hydrazino", alone or in combination, means a -NH-NH-  
10 group wherein the remaining two bonds (valences) are independently substituted. The hydrogen atoms of the hydrazino group can be replaced, independently, with substituents and the nitrogen atoms can form acid addition salts or be quaternized.

15 The term "sulfonyl", alone or in combination, means a -S(=O)<sub>2</sub>- group wherein the remaining two bonds (valences) can be independently substituted. The term "sulfoxido", alone or in combination, means a -S(=O)<sub>1</sub>- group wherein the remaining two bonds (valences) can be  
20 independently substituted. The term "sulfonylamide", alone or in combination, means a -S(=O)<sub>2</sub>-N= group wherein the remaining three bonds (valences) can be independently substituted. The term "sulfinamido", alone or in combination, means a -S(=O)<sub>1</sub>N= group  
25 wherein the remaining three bonds (valences) can be independently substituted. The term "sulfenamide", alone or in combination, means a -S-N= group wherein the remaining three bonds (valences) can be independently substituted.

30 The term "alkoxy", alone or in combination, means an alkyl ether radical wherein the term alkyl is

as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like. The term "cycloalkyl", alone or in combination, means an alkyl radical which contains from about 3 to about 8 carbon atoms and is cyclic. The term "cycloalkylalkyl" means an alkyl radical as defined above which is substituted by a cycloalkyl radical containing from about 3 to about 8, preferably from about 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

The term "aryl", alone or in combination, means a phenyl, indenyl or naphthyl radical that optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like.

The term "aralkyl", alone or in combination, means an alkyl radical as defined above in which one hydrogen atom is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like. The term "aralkoxycarbonyl", alone or in combination, means a radical of the formula  $-C(O)-O-$ aralkyl in which the term "aralkyl" has the significance given above. An example of an aralkoxycarbonyl radical is benzyloxycarbonyl. The term "aryloxy" means a radical of the formula aryl-O- in which the term aryl has the significance given above. The term "aromatic ring" in combinations such as substituted-aromatic ring

sulfonamide, substituted-aromatic ring sulfinamide or substituted-aromatic ring sulfenamide means aryl or heteroaryl as defined above.

The terms "alkanoyl" or "alkylcarbonyl", 5 alone or in combination, means an acyl radical derived from an alkylcarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like. The term "cycloalkylcarbonyl" means an acyl group derived from a monocyclic or bridged 10 cycloalkylcarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkylcarboxylic acid which is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl, 15 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl. The terms "aralkanoyl" or "aralkylcarbonyl" mean an acyl radical derived from an aryl-substituted alkylcarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 20 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl and the like.

The terms "aroyl" or "arylcarbonyl" means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic 25 acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2 naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-30 naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like.

The heterocyclyl (heterocyclo) or heterocycloalkyl portion of a heterocyclylcarbonyl, heterocyclloxycarbonyl, heterocyclalkoxycarbonyl, or heterocyclalkyl group or the like is a saturated or 5 partially unsaturated monocyclic, bicyclic or tricyclic heterocycle that contains one or more hetero atoms selected from nitrogen, oxygen and sulphur, which is optionally substituted on one or more carbon atoms by a halogen, alkyl, alkoxy, oxo group, and the like, 10 and/or on a secondary nitrogen atom (i.e., -NH-) by an alkyl, aralkoxycarbonyl, alkanoyl, aryl or arylalkyl or on a tertiary nitrogen atom (i.e. =N-) by oxido and which is attached via a carbon atom. The tertiary nitrogen atom with three substituents can also form a 15 N-oxide (=N(O)-) group. The heteroaryl portion of a heteroaroyl, heteroaryloxycarbonyl, or a heteroaralkoxy carbonyl group or the like is an aromatic monocyclic, bicyclic, or tricyclic heterocycle that contains the hetero atoms and is optionally substituted as defined 20 above with respect to the definition of heterocyclyl. Examples of such heterocyclyl and heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol 4-yl, 1-benzyloxycarbonyl-imidazol-4-yl, pyrazolyl, 25 pyridyl, pyrazinyl, pyrimidinyl, furyl, tetrahydrofuryl, thienyl, triazolyl, oxazolyl, oxadiazoyl, thiazoyl, thiadiazoyl, indolyl (e.g., 2-indolyl, quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl), isoquinolinyl (e.g., 1- 30 isoquinolinyl, 3-isoquinolinyl), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl),

1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl), quinoxalinyl,  $\beta$ -carbolinyl, 2-benzofurancarbonyl, benzothiophenyl, 1-, 2-, 4- or 5-benzimidazolyl, and the like.

5        The term "cycloalkylalkoxycarbonyl" means an acyl group derived from a cycloalkylalkoxycarboxylic acid of the formula cycloalkylalkyl-O-COOH wherein cycloalkylalkyl has the significance given above. The term "aryloxyalkanoyl" means an acyl radical of the 10 formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term "heterocyclyloxycarbonyl" means an acyl group derived from heterocyclyl-O-COOH wherein heterocyclyl is as defined above. The term "heterocyclylalkanoyl" is an 15 acyl radical derived from a heterocyclyl-substituted alkane carboxylic acid wherein heterocyclyl has the significance given above. The term "heterocyclylalkoxycarbonyl" means an acyl radical derived from a heterocyclyl-substituted alkane-O-COOH 20 wherein heterocyclyl has the significance given above. The term "heteroaryloxy carbonyl" means an acyl radical derived from a carboxylic acid represented by heteroaryl-O-COOH wherein heteroaryl has the significance given above.

25        The term "aminocarbonyl" alone or in combination, means an amino-substituted carbonyl (carbamoyl) group derived from an amino-substituted carboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing 30 substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the

like. The term "aminoalkanoyl" means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents

5 independently selected from hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like.

The term "halogen" means fluorine, chlorine, bromine or iodine. The term "haloalkyl" means an alkyl 10 radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl 15 and the like. The term perfluoroalkyl means an alkyl group wherein each hydrogen has been replaced by a fluorine atom. Examples of such perfluoroalkyl groups, in addition to trifluoromethyl above, are perfluorobutyl, perfluoroisopropyl, perfluorododecyl 20 and perfluorodecyl.


#### Description of the Preferred Embodiments

In accordance with the present invention, it has been discovered that certain novel substituted-25 aromatic sulfonamide hydroxamic acid compounds are effective for inhibition of matrix metalloproteases ("MMPs") believed to be associated with uncontrolled or otherwise pathological breakdown of connective tissue. In particular, it has been found that these 30 substituted-aromatic ring sulfonamide hydroxamic acid, substituted-aromatic ring sulfinamide hydroxamic acid

or substituted-aromatic ring sulfenamide hydroxamic acid compounds are effective for inhibition of collagenase Type III (MMP-13), which is believed to be particularly destructive to tissue if present or 5 generated in abnormal quantities or concentrations. Moreover, it has been discovered that many of these novel sulfur-nitrogen bonded compounds are selective in the inhibition of MMP-13 and/or other MMPs associated with diseased conditions without excessive inhibition 10 of those collagenases essential to normal bodily function such as tissue turnover and repair or other zinc proteases. More particularly, it has been found that many of the substituted-aryl- or substituted-heteroaryl-sulfonamide hydroxamic acids of the 15 invention are selective for MMP-13 with limited or minimal effect on MMP-1.

Set forth in Table 1 to Table 8 inclusive and in Example 1 to Example 15 inclusive are several series 20 of preferred classes of compounds.

TABLE 1



Example	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>
4			
5			
6			
7			
8			
9			
10			
11			

Table 1  
(continued)


















12			
13			
14			
15			
16			
17			

TABLE 2



Example	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>
18			
19			
20			
21			
22			
23			
24			
25			

- 27 -

Table 2  
(continued)
































26			
27			
28			
29			
30			
31			

TABLE 3




Example	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>
32			
33			
34			
35			
36			
37			
38			
39			

Table 3  
(continued)

40			
41			
42			
43			
44			
45			

-30-

TABLE 4



Example	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>
46			
47			
48			
49			
50			
51			
52			
53			

-31-

Table 4  
(continued)















54			
55			
56			
57			
58			
59			

TABLE 5



5

Example	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
4		—CH <sub>3</sub>	
5		H <sub>3</sub> C   CH <sub>3</sub>	
6		CH <sub>3</sub>   CH <sub>3</sub>	
7			
8		—CH <sub>3</sub>	
9		H <sub>3</sub> C   CH <sub>3</sub>	
10		CH <sub>3</sub>   CH <sub>3</sub>	
11			

- 33 -

Table 5  
(continued)

12	—CH <sub>3</sub>	—CH <sub>3</sub>	
13	—CH <sub>3</sub>		
14	—CH <sub>3</sub>		
15	—CH <sub>3</sub>		
16		—CH <sub>3</sub>	
17			
18			
19			
20		—CH <sub>3</sub>	
21			
22			

Table 5  
(continued)

23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			

-35-

Table 5  
(continued)






























34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			

Table 5  
(continued)

45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			

-37-

Table 5  
(continued)































56		$\text{---CH}_3$	
57		$\text{H}_3\text{C}$ 	
58			
59			
60		$\text{---CH}_3$	
61		$\text{H}_3\text{C}$ 	
62			
63			
64		$\text{---CH}_3$	
65		$\text{H}_3\text{C}$ 	
66			

Table 5  
(continued)

67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			

Table 5  
(continued)













































78			
79			
80			
81			
82			
83			
84			
85			
86			
87			

Table 5  
(continued)

88		—CH <sub>3</sub>	
89		H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	
90		CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	
91		H <sub>3</sub> C—NH—CH <sub>2</sub> —C(=O)N—CH <sub>3</sub>	
92	—CH <sub>3</sub>	—CH <sub>3</sub>	
93	—CH <sub>3</sub>	H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	
94	—CH <sub>3</sub>	CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	
95	—CH <sub>3</sub>	H <sub>3</sub> C—NH—CH <sub>2</sub> —C(=O)N—CH <sub>3</sub>	
96	CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	—CH <sub>3</sub>	
97	CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	
98	CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	

-41-

Table 5  
(continued)






























99			
100			
101			
102			
103			
104			
105			
106			
107			
108			

Table 5  
(continued)
































109			
110			
111			
112			
113			
114			
115			
116			
117			
118			
119			

Table 5  
(continued)























120		—CH <sub>3</sub>	
121		H <sub>3</sub> C   CH <sub>3</sub>	
122		CH <sub>3</sub>   CH <sub>3</sub>	
123		CH <sub>3</sub>   CH <sub>2</sub> —NH—C(=O)CH <sub>2</sub> —N(CH <sub>3</sub> ) <sub>2</sub>	
124		—CH <sub>3</sub>	
125		H <sub>3</sub> C   CH <sub>3</sub>	
126		CH <sub>3</sub>   CH <sub>3</sub>	
127		CH <sub>3</sub>   CH <sub>2</sub> —NH—C(=O)CH <sub>2</sub> —N(CH <sub>3</sub> ) <sub>2</sub>	
128		—CH <sub>3</sub>	
129		H <sub>3</sub> C   CH <sub>3</sub>	
130		CH <sub>3</sub>   CH <sub>3</sub>	

Table 5  
(continued)



























131			
132	—CH <sub>3</sub>	—CH <sub>3</sub>	
133	—CH <sub>3</sub>		
134	—CH <sub>3</sub>		
135	—CH <sub>3</sub>		
136		—CH <sub>3</sub>	
137			
138			
139			
140		—CH <sub>3</sub>	
141			

Table 5  
(continued)

142			
143			
144			
145			
146			
147			
148			
149			
150			
151			
152			

Table 5  
(continued)











153	—CH <sub>3</sub>		
154	—CH <sub>3</sub>		
155	—CH <sub>3</sub>		
156		—CH <sub>3</sub>	
157			
158			
159			
160		—CH <sub>3</sub>	
161			
162			
163			

Table 5  
(continued)



























164			
165			
166			
167			
168			
169			
170			
171			
172			
173			
174			

Table 5  
(continued)

























175			
176			
177			
178			
179			
180			
181			
182			
183			
184			
185			

Table 5  
(continued)

186			
187			
188			
189			
190			
191			
192			
193			
194			
195			
196			

-50-

Table 5  
(continued)



























197			
198			
199			
200			
201			
202			
203			
204			
205			
206			
207			

Table 5  
(continued)

208		$\text{---CH}_3$	
209		$\text{H}_3\text{C} \begin{array}{c}   \\ \text{---} \\   \\ \text{CH}_3 \end{array}$	
210		$\text{---CH}_3$	
211		$\text{H}_3\text{C} \begin{array}{c}   \\ \text{---} \\   \\ \text{CH}_3 \end{array} \begin{array}{c}   \\ \text{---} \\   \\ \text{N} \end{array} \text{---CH}_3$	
212	$\text{---CH}_3$	$\text{---CH}_3$	
213	$\text{---CH}_3$	$\text{H}_3\text{C} \begin{array}{c}   \\ \text{---} \\   \\ \text{CH}_3 \end{array}$	
214	$\text{---CH}_3$	$\text{---CH}_3$	
215	$\text{---CH}_3$	$\text{H}_3\text{C} \begin{array}{c}   \\ \text{---} \\   \\ \text{CH}_3 \end{array} \begin{array}{c}   \\ \text{---} \\   \\ \text{N} \end{array} \text{---CH}_3$	
216		$\text{---CH}_3$	
217		$\text{H}_3\text{C} \begin{array}{c}   \\ \text{---} \\   \\ \text{CH}_3 \end{array}$	
218		$\text{---CH}_3$	

Table 5  
(continued)




























219			
220			
221			
222			
223			
224			
225			
226			
227			
228			
229			

Table 5  
(continued)





























230			
231			
232			
233			
234			
235			
236			
237			
238			
239			
240			

Table 5  
(continued)

241			
242			
243			
244			
245			
246			
247			
248			
249			
250			
251			

-55-

Table 5  
(continued)





























252			
253			
254			
255			
256			
257			
258			
259			
260			
261			
262			

Table 5  
(continued)





















263			
264		—CH <sub>3</sub>	
265			
266			
267			
268		—CH <sub>3</sub>	
269			
270			
271			
272	—CH <sub>3</sub>	—CH <sub>3</sub>	
273	—CH <sub>3</sub>		

Table 5  
(continued)





















































274			
275			
276			
277			
278			
279			
280			
281			
282			
283			
284			

Table 5  
(continued)

285			
286			
287			
288			
289			
290			
291			
292			
293			
294			
295			


- 59 -

Table 5  
(continued)

296			
297			
298			
299			
300			
301			
302			
303			

-60-

Table 6



Example	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
304		—CH <sub>3</sub>	
305		H <sub>3</sub> C   CH <sub>3</sub>	
306		—CH <sub>3</sub>   CH <sub>3</sub>	
307			
308		—CH <sub>3</sub>	
309		H <sub>3</sub> C   CH <sub>3</sub>	
310		—CH <sub>3</sub>   CH <sub>3</sub>	
311			

Table 6  
(continued)



















312	—CH <sub>3</sub>	—CH <sub>3</sub>	
313	—CH <sub>3</sub>	H <sub>3</sub> C   C—CH <sub>3</sub>	
314	—CH <sub>3</sub>	CH <sub>3</sub>   C—CH <sub>3</sub>	
315	—CH <sub>3</sub>		
316		—CH <sub>3</sub>	
317		H <sub>3</sub> C   C—CH <sub>3</sub>	
318		CH <sub>3</sub>   C—CH <sub>3</sub>	
319			
320		—CH <sub>3</sub>	
321		H <sub>3</sub> C   C—CH <sub>3</sub>	
322		CH <sub>3</sub>   C—CH <sub>3</sub>	

Table 6  
(continued)

323			
324		—CH <sub>3</sub>	
325		H <sub>3</sub> C CH <sub>3</sub>	
326		CH <sub>3</sub> CH <sub>3</sub>	
327			
328		—CH <sub>3</sub>	
329		H <sub>3</sub> C CH <sub>3</sub>	
330		CH <sub>3</sub> CH <sub>3</sub>	
331			
332	—CH <sub>3</sub>	—CH <sub>3</sub>	
333	—CH <sub>3</sub>	H <sub>3</sub> C CH <sub>3</sub>	

- 63 -

Table 6  
(continued)





























334			
335			
336			
337			
338			
339			
340			
341			
342			
343			
344			

Table 6  
(continued)






















































345			
346			
347			
348			
349			
350			
351			
352			
353			
354			
355			

Table 6  
(continued)

356			
357			
358			
359			
360			
361			
362			
363			
364			
365			

-66-

Table 6  
(continued)

366			
367			
368			
369			
370			
371			
372			
373			
374			

Table 6  
(continued)




























375			
376			
377			
378			
379			
380			
381			
382			
383			

Table 6  
(continued)























































384			
385			
386			
387			
388			
389			
390			
391			
392			
393			
394			

Table 6  
(continued)

395			
396			
397			
398			
399			
400			
401			
402			
403			
404			

-70-

Table 6  
(continued)

































405			
406			
407			
408			
409			
410			
411			
412			
413			
414			
415			

Table 6  
(continued)



























416			
417			
418			
419			
420			
421			
422			
423			
424			
425			

Table 6  
(continued)






























426			
427			
428			
429			
430			
431			
432			
433			
434			
435			
436			

Table 6  
(continued)

437			
438			
439			
440			
441			
442			
443			
444			
445			
446			

Table 6  
(continued)

447			
448			
449			
450			
451			
452			
453			
454			
455			
456			
457			

Table 6  
(continued)


















































































458			
459			
460			
461			
462			
463			
464			
465			
466			
467			
468			

Table 6  
(continued)

469			
470			
471			
472			
473			
474			
475			
476			
477			
478			
479			

-77-

Table 6  
(continued)

480		—CH <sub>3</sub>	
481		H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	
482		CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	
483			
484		—CH <sub>3</sub>	
485		H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	
486		CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	
487			
488		—CH <sub>3</sub>	
489		H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	

-78-

Table 6  
(continued)


































490			
491			
492			
493			
494			
495			
496			
497			
498			
499			
500			

Table 6  
(continued)

501			
502			
503			
504			
505			
506			
507			
508			
509			
510			
511			

- 80 -

Table 6  
(continued)

































512			
513			
514			
515			
516			
517			
518			
519			
520			
521			
522			

Table 6  
(continued)

523			
524		—CH <sub>3</sub>	
525		H <sub>3</sub> C CH <sub>3</sub>	
526		CH <sub>3</sub> CH <sub>3</sub>	
527			
528		—CH <sub>3</sub>	
529		H <sub>3</sub> C CH <sub>3</sub>	
530		CH <sub>3</sub> CH <sub>3</sub>	
531			
532	—CH <sub>3</sub>	—CH <sub>3</sub>	
533	—CH <sub>3</sub>	H <sub>3</sub> C CH <sub>3</sub>	

Table 6  
(continued)
































534			
535			
536			
537			
538			
539			
540			
541			
542			
543			
544			

Table 6  
(continued)

































545			
546			
547			
548			
549			
550			
551			
552			
553			
554			
555			

Table 6  
(continued)
























556			
557			
558			
559			
560			
561			
562			
563			

Table 7



5

Example	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
564		—CH <sub>3</sub>	
565		H <sub>3</sub> C CH <sub>3</sub>	
566		CH <sub>3</sub> CH <sub>3</sub>	
567		CH <sub>3</sub> NH-C(=O)-CH <sub>2</sub> -N(CH <sub>3</sub> ) <sub>2</sub>	
568		—CH <sub>3</sub>	
569		H <sub>3</sub> C CH <sub>3</sub>	
570		CH <sub>3</sub> CH <sub>3</sub>	
571		CH <sub>3</sub> NH-C(=O)-CH <sub>2</sub> -N(CH <sub>3</sub> ) <sub>2</sub>	
572	—CH <sub>3</sub>	—CH <sub>3</sub>	

Table 7  
(continued)



























573	—CH <sub>3</sub>		
574	—CH <sub>3</sub>		
575	—CH <sub>3</sub>		
576		—CH <sub>3</sub>	
577			
578			
579	—CH		
580		—CH <sub>3</sub>	
581			
582			
583			

Table 7  
(continued)



































584		—CH <sub>3</sub>	—CH <sub>3</sub>
585		H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	—CH <sub>3</sub>
586		CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	—CH <sub>3</sub>
587			—CH <sub>3</sub>
588		—CH <sub>3</sub>	—CH <sub>3</sub>
589		H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	—CH <sub>3</sub>
590		CH <sub>3</sub>   CH <sub>3</sub> —CH <sub>3</sub>	—CH <sub>3</sub>
591			—CH <sub>3</sub>
592	—CH <sub>3</sub>	—CH <sub>3</sub>	—CH <sub>3</sub>
593	—CH <sub>3</sub>		—CH <sub>3</sub>
594	—CH <sub>3</sub>	H <sub>3</sub> C   CH <sub>3</sub> —CH <sub>3</sub>	—CH <sub>3</sub>
595	—CH <sub>3</sub>		—CH <sub>3</sub>

Table 7  
(continued)

596		—CH <sub>3</sub>	—CH <sub>3</sub>
597			—CH <sub>3</sub>
598			—CH <sub>3</sub>
599			—CH <sub>3</sub>
600		—CH <sub>3</sub>	—CH <sub>3</sub>
601			—CH <sub>3</sub>
602			—CH <sub>3</sub>
603			—CH <sub>3</sub>
604		—CH <sub>3</sub>	
605			
606			

- 89 -

Table 7  
(continued)

607			
608		—CH <sub>3</sub>	
609			
610			
611			
612	—CH <sub>3</sub>	—CH <sub>3</sub>	
613	—CH <sub>3</sub>		
614	—CH <sub>3</sub>		
615	—CH <sub>3</sub>		
616		—CH <sub>3</sub>	
617			

-90-

Table 7  
(continued)


















































618			
619			
620			
621			
622			
623			
624			
625			
626			
627			

Table 7  
(continued)

628		$-\text{CH}_3$	
629		$\text{H}_3\text{C}-\text{CH}_3$	
630		$\text{CH}_3-\text{CH}_3$	
631			
632	$-\text{CH}_3$	$-\text{CH}_3$	
633	$-\text{CH}_3$	$\text{H}_3\text{C}-\text{CH}_3$	
634	$-\text{CH}_3$	$\text{CH}_3-\text{CH}_3$	
635	$-\text{CH}_3$		
636		$-\text{CH}_3$	
637		$\text{H}_3\text{C}-\text{CH}_3$	
638		$\text{CH}_3-\text{CH}_3$	

- 92 -

Table 7  
(continued)





























639			
640			
641			
642			
643			
644			
645			
646			
647			
648			
649			

Table 7  
(continued)































650			
651			
652			
653			
654			
655			
656			
657			
658			
659			
660			

Table 7  
(continued)

































661			
662			
663			
664			
665			
666			
667			
668			
669			
670			
671			

Table 7  
(continued)
























































672	$\text{---CH}_3$	$\text{---CH}_3$	
673	$\text{---CH}_3$	$\text{H}_3\text{C---CH}_3$	
674	$\text{---CH}_3$	$\text{CH}_3$ $\text{---CH}_3$	
675	$\text{---CH}_3$	$\text{---CH}_2\text{NHCOCH}_2\text{N---CH}_3$	
676	$\text{CH}_3$ $\text{---CH}_2\text{CH}_2\text{CH}_3$	$\text{---CH}_3$	
677	$\text{CH}_3$ $\text{---CH}_2\text{CH}_2\text{CH}_3$	$\text{H}_3\text{C---CH}_2\text{CH}_3$	
678	$\text{CH}_3$ $\text{---CH}_2\text{CH}_2\text{CH}_3$	$\text{CH}_3$ $\text{---CH}_2\text{CH}_3$	
679	$\text{CH}_3$ $\text{---CH}_2\text{CH}_2\text{CH}_3$	$\text{---CH}_2\text{NHCOCH}_2\text{N---CH}_3$	
680	$\text{---CH}_2\text{NHCOCH}_2\text{N---CH}_3$	$\text{---CH}_3$	
681	$\text{---CH}_2\text{NHCOCH}_2\text{N---CH}_3$	$\text{H}_3\text{C---CH}_2\text{CH}_3$	
682	$\text{---CH}_2\text{NHCOCH}_2\text{N---CH}_3$	$\text{CH}_3$ $\text{---CH}_2\text{CH}_3$	

Table 7  
(continued)

683			
684		—CH <sub>3</sub>	
685		H <sub>3</sub> C   CH <sub>3</sub>	
686		CH <sub>3</sub>   CH <sub>3</sub>	
687			
688		—CH <sub>3</sub>	
689		CH <sub>3</sub>   CH <sub>3</sub>	
690		CH <sub>3</sub>   CH <sub>3</sub>	
691			
692	—CH <sub>3</sub>	—CH <sub>3</sub>	
693	—CH <sub>3</sub>	CH <sub>3</sub>   CH <sub>3</sub>	
694	—CH <sub>3</sub>	CH <sub>3</sub>   CH <sub>3</sub>	






























- 97 -

Table 7  
(continued)

695			
696			
697			
698			
699			
700			
701			
702			
703			
704			
705			


































- 98 -

Table 7  
(continued)

706			
707			
708			
709			
710			
711			
712			
713			
714			
715			
716			

-99-

Table 7  
(continued)

717			
718			
719			
720			
721			
722			
723			
724			
725			
726			
727			

-100-

Table 7  
(continued)

728			
729			
730			
731			
732			
733			
734			
735			
736			
737			
738			

Table 7  
(continued)































































739			
740			
741			
742			
743			
744			
745			
746			
747			
748			
749			

Table 7  
(continued)


750			
751			
752			
753			
754			
755			
756			
757			
758			
759			
760			

-103-

Table 7  
(continued)

761			
762			
763			

Table 8



5

Example	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>
764		—CH <sub>3</sub>	
765		H <sub>3</sub> C CH <sub>3</sub>	
766		CH <sub>3</sub> CH <sub>3</sub>	
767			
768		—CH <sub>3</sub>	
769		H <sub>3</sub> C CH <sub>3</sub>	
770		CH <sub>3</sub> CH <sub>3</sub>	
771			

-105-

Table 8  
(continued)



























772	$\text{---CH}_3$	$\text{---CH}_3$	
773	$\text{---CH}_3$		
774	$\text{---CH}_3$		
775	$\text{---CH}_3$		
776		$\text{---CH}_3$	
777			
778			
779			
780		$\text{---CH}_3$	
781			
782			

Table 8  
(continued)



















783			
784		—CH <sub>3</sub>	
785		H <sub>3</sub> C CH <sub>3</sub>	
786		CH <sub>3</sub> CH <sub>3</sub>	
787			
788		—CH <sub>3</sub>	
789		H <sub>3</sub> C CH <sub>3</sub>	
790		CH <sub>3</sub> CH <sub>3</sub>	
791			
792	—CH <sub>3</sub>	—CH <sub>3</sub>	

Table 8  
(continued)


























793	—CH <sub>3</sub>		
794	—CH <sub>3</sub>		
795	—CH <sub>3</sub>		
796		—CH <sub>3</sub>	
797			
798			
799			
800		—CH <sub>3</sub>	
801			
802			

Table 8  
(continued)









































































803			
804		—CH <sub>3</sub>	
805		H <sub>3</sub> C CH <sub>3</sub>	
806		CH <sub>3</sub> CH <sub>3</sub>	
807			
808		—CH <sub>3</sub>	
809		H <sub>3</sub> C CH <sub>3</sub>	
810		CH <sub>3</sub> CH <sub>3</sub>	
811			
812	—CH <sub>3</sub>	—CH <sub>3</sub>	
813	—CH <sub>3</sub>	H <sub>3</sub> C CH <sub>3</sub>	

Table 8  
(continued)

814	—CH <sub>3</sub>		
815	—CH <sub>3</sub>		
816		—CH <sub>3</sub>	
817			
818			
819			
820		—CH <sub>3</sub>	
821			
822			
823			
824		—CH <sub>3</sub>	

-110-

Table 8  
(continued)

825			
826			
827			
828			
829			
830			
831			
832			
833			
834			
835			

-111-

Table 8  
(continued)



























836			
837			
838			
839			
840			
841			
842			
843			
844			
845			

Table 8  
(continued)

































846			—NH <sub>2</sub>
847			—NH <sub>2</sub>
848		—CH <sub>3</sub>	—NH <sub>2</sub>
849			—NH <sub>2</sub>
850			—NH <sub>2</sub>
851			—NH <sub>2</sub>
852	—CH <sub>3</sub>	—CH <sub>3</sub>	—NH <sub>2</sub>
853	—CH <sub>3</sub>		—NH <sub>2</sub>
854	—CH <sub>3</sub>		—NH <sub>2</sub>
855	—CH <sub>3</sub>		—NH <sub>2</sub>
856		—CH <sub>3</sub>	—NH <sub>2</sub>
857			—NH <sub>2</sub>

Table 8  
(continued)

858			—NH <sub>2</sub>
859			—NH <sub>2</sub>
860		—CH <sub>3</sub>	—NH <sub>2</sub>
861			—NH <sub>2</sub>
862			—NH <sub>2</sub>
863			—NH <sub>2</sub>
864		—CH <sub>3</sub>	—N—Cyclohexyl
865			—N—Cyclohexyl
866			—N—Cyclohexyl
867			—N—Cyclohexyl

-114-

Table 8  
(continued)



















868		$\text{---CH}_3$	
869		$\text{H}_3\text{C} \begin{matrix}   \\ \text{---} \\   \\ \text{CH}_3 \end{matrix}$	
870		$\text{CH}_3 \begin{matrix}   \\ \text{---} \\   \\ \text{CH}_3 \end{matrix}$	
871		$\text{CH}_3\text{CH}_2\text{NHCOCH}_2\text{N}(\text{CH}_3)_2$	
872	$\text{---CH}_3$	$\text{---CH}_3$	
873	$\text{---CH}_3$	$\text{H}_3\text{C} \begin{matrix}   \\ \text{---} \\   \\ \text{CH}_3 \end{matrix}$	
874	$\text{---CH}_3$	$\text{CH}_3 \begin{matrix}   \\ \text{---} \\   \\ \text{CH}_3 \end{matrix}$	
875	$\text{---CH}_3$	$\text{CH}_3\text{CH}_2\text{NHCOCH}_2\text{N}(\text{CH}_3)_2$	
876		$\text{---CH}_3$	
877		$\text{H}_3\text{C} \begin{matrix}   \\ \text{---} \\   \\ \text{CH}_3 \end{matrix}$	
878		$\text{CH}_3 \begin{matrix}   \\ \text{---} \\   \\ \text{CH}_3 \end{matrix}$	

Table 8  
(continued)




























879			
880			
881			
882			
883			
884			
885			
886			
887			
888			
889			

Table 8  
(continued)

890			
891			
892			
893			
894			
895			
896			
897			
898			
899			
900			

Table 8  
(continued)





















































901			
902			
903			
904			
905			
906			
907			
908			
909			
910			
911			

Table 8  
(continued)

912	—CH <sub>3</sub>	—CH <sub>3</sub>	
913	—CH <sub>3</sub>		
914	—CH <sub>3</sub>		
915	—CH <sub>3</sub>		
916		—CH <sub>3</sub>	
917			
918			
919			
920		—CH <sub>3</sub>	
921			
922			

Table 8  
(continued)

923			
924			
925			
926			
927			
928			
929			
930			
931			
932			
933			

-120-

Table 8  
(continued)



























































934			
935			
936			
937			
938			
939			
940			
941			
942			
943			
944			

Table 8  
(continued)

945			
946			
947			
948			
949			
950			
951			
952			
953			
954			
955			
956			

Table 8  
(continued)

957			
958			
959			
960			
961			
962			
963			
964			
965			
966			

-123-

Table 8  
(continued)

967			
968			
969			
970			
971			
972			
973			
974			
975			
976			
977			

-124-

Table 8  
(continued)

































978			
979			
980			
981			
982			
983			
984			
985			
986			
987			
988			

Table 8  
(continued)

989			
990			
991			
992			
993			
994			
995			
996			
997			
998			
999			

Table 8  
(continued)


















1000		—CH <sub>3</sub>	
1001		H <sub>3</sub> C   CH <sub>3</sub>	
1002		CH <sub>3</sub>   CH <sub>3</sub>	
1003		CH <sub>3</sub>   CH <sub>2</sub> —NH—C(=O)N <sub>2</sub>	
1004		—CH <sub>3</sub>	
1005		H <sub>3</sub> C   CH <sub>3</sub>	
1006		CH <sub>3</sub>   CH <sub>3</sub>	
1007		CH <sub>3</sub>   CH <sub>2</sub> —NH—C(=O)N <sub>2</sub>	
1008		—CH <sub>3</sub>	
1009		H <sub>3</sub> C   CH <sub>3</sub>	
1010		CH <sub>3</sub>   CH <sub>3</sub>	

Table 8  
(continued)






















1011			
1012			
1013			
1014			
1015			
1016			
1017			
1018			
1019			
1020			
1021			

Table 8  
(continued)
























































1022			
1023			
1024			
1025			
1026			
1027			
1028			
1029			
1030			
1031			
1032			

Table 8  
(continued)

1033	—CH <sub>3</sub>		
1034	—CH <sub>3</sub>		
1035	—CH <sub>3</sub>		
1036		—CH <sub>3</sub>	
1037			
1038			
1039			
1040		—CH <sub>3</sub>	
1041			
1042			
1043			

Treatment Process

A process for treating a host mammal having a condition associated with pathological matrix

5 metalloprotease activity is also contemplated. That process comprises administering a metalloprotease inhibitor described hereinbefore in an MMP enzyme-inhibiting effective amount to a mammalian host having such a condition. The use of administration repeated a 10 plurality of times is particularly contemplated.

A contemplated inhibitor compound is used for treating a host mammal such as a mouse, rat, rabbit, dog, horse, primate such as a monkey, chimpanzee or human that has a condition associated with pathological 15 matrix metalloprotease activity.

Also contemplated is the similar use of a contemplated metalloprotease inhibitor compound in the treatment of a disease state that can be affected by the activity of metalloproteases such as TNF- $\alpha$  20 convertase. Exemplary of such disease states are the acute phase responses of shock and sepsis, coagulation responses, hemorrhage and cardiovascular effects, fever and inflammation, anorexia and cachexia.

In treating a disease condition associated 25 with pathological matrix metalloproteinase activity, a contemplated MMP inhibitor compound can be used, where appropriate, in the form of an amine salt derived from an inorganic or organic acid. Exemplary acid salts include but are not limited to the following: acetate, 30 adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate,

-131-

dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, 5 methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate.

10 Also, a basic nitrogen-containing group can be quaternized with such agents as lower alkyl (C<sub>1</sub>-C<sub>6</sub>) halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long 15 chain (C<sub>8</sub>-C<sub>20</sub>) halides such as decyl, lauryl, myristyl and dodecyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others to provide enhanced water-solubility. Water or oil-soluble or dispersible products are thereby obtained as 20 desired. The salts are formed by combining the basic compounds with the desired acid.

Other compounds useful in this invention that are acids can also form salts. Examples include salts with alkali metals or alkaline earth metals, such as 25 sodium, potassium, calcium or magnesium or with organic bases or basic quaternary ammonium salts.

In some cases, the salts can also be used as an aid in the isolation, purification or resolution of the compounds of this invention.

30 Total daily dose administered to a host mammal in single or divided doses of an MMP enzyme-

inhibiting effective amount can be in amounts, for example, of about 0.001 to about 30 mg/kg body weight daily and more usually about 0.01 to about 10 mg.

5 Dosage unit compositions can contain such amounts or submultiples thereof to make up the daily dose. A suitable dose can be administered, in multiple sub-doses per day. Multiple doses per day can also increase the total daily dose, should such dosing be desired by the person prescribing the drug.

10 The dosage regimen for treating a disease condition with a compound and/or composition of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the 15 disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is 20 administered as part of a drug combination. Thus, the dosage regimen actually employed can vary widely and therefore can deviate from the preferred dosage regimen set forth above.

25 A compound useful in the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, parenterally, by inhalation spray, rectally, or 30 topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal

administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania; 1975 and Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and 5 polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and 10 granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, 15 cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for 20 convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of 25 capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

30 For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous

or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in 5 the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and 10 modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing 15 inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be 20 combined with the carrier materials to produce a single dosage form varies depending upon the mammalian host treated and the particular mode of administration.

Certain of the sulfonamide, sulfinamide or sulfenamide, compounds of this invention that are 25 administered in accordance with an above-discussed process can serve as prodrugs to other compounds of this invention. Prodrugs are drugs that can be chemically converted *in vivo* or *in vitro* by biological systems into an active derivative or derivatives. 30 Prodrugs are administered in essentially the same manner as the other pharmaceutical compounds of the

invention. Exemplary prodrugs correspond in structure to a compound of formula VII in which R<sup>14</sup> is acyl.

Preparation of Useful Compounds

5 Expressly included among the individual compounds of the present invention are carboxylic acid compounds corresponding to each of the hydroxamic acid compounds of Tables 1-8. Each such carboxylic acid compound has the structure depicted for the  
10 corresponding hydroxamic acid compound of the tables, except that the carboxylic acid contains an -OH group in the same location in the structure as the HO-NH- group of the hydroxamic acid. Thus, the invention specifically includes a carboxylic acid compound  
15 corresponding to each of: Examples 4-17 of Table 1; Examples 18-31 of Table 2; Examples 32-45 of Table 3; Examples 46-59 of Table 4; Examples 4-303 of Table 5; Examples 304-563 of Table 6; Examples 564-763 of Table 7; and Examples 764-1043 of Table 8. The invention  
20 also specifically includes the carboxylic acid compounds corresponding to each of working Examples 1-4 that are provided hereinafter.

Schemes I and III and Schemes 1, 2, 4, 5, 6, and 7 illustrate procedures with examples of chemical  
25 transformations that may be useful for the preparation of compounds of this invention. These syntheses, as with all of the reactions discussed herein, can be carried out under a dry inert atmosphere such a nitrogen or argon if desired. Selected reactions known  
30 to those skilled in the art, can be carried out under a dry atmosphere such as dry air whereas other synthetic

steps, for example, aqueous acid or base ester or amide hydrolyses, can be carried out under laboratory air.


Thus, in general, the choices of starting material and reaction conditions can vary as is well known to those skilled in the art. Usually, no single set of conditions is limiting since variations can be applied as required. Conditions will also will be selected as desired to suit a specific purpose such as small scale preparations or large scale preparations.

5 In either case, the use of less safe or less environmentally sound materials or reagents will usually be minimized. Examples of such less desirable materials are diazomethane, diethyl ether, heavy metal salts, dimethyl sulfide, chloroform, benzene and the

10 like.

15

Scheme I



Scheme 1 shows the conversion of an N-substituted alpha-amino acid, protected or unprotected, into a compound of Formula I. The amino acid may be protected with a group P such as an alkyl 5 ester such as methyl, ethyl, tert-butyl, tetrahydropyranyl and the like or arylalkyl ester such as benzyl. Treatment of this amine with a sulfonyl, sulfinyl or sulfenyl chloride would provide the corresponding amide. A base would normally be used to 10 inactivate the HCl released from the acid chloride and it would be such that it would not react with the sulfonyl chloride, i.e., ammonia, I° or II° amines would not normally be used. Examples of bases that can be used include, for example, metal hydroxides such as 15 sodium, potassium, lithium or magnesium hydroxide, oxides such as those of sodium, potassium, lithium, calcium or magnesium, metal carbonates such as those of sodium, potassium, lithium, calcium or magnesium, metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, I°, II° or III° organic amines such as 20 alkyl amines, arylalkyl amines, alkylarylalkyl amines, heterocyclic amines or heteroaryl amines, ammonium hydroxides or quaternary ammonium hydroxides. As non-limiting examples, such amines can include triethylamine, trimethyl amine, diisopropyl amine, 25 methyldiisopropyl amine, diazabicyclononane, tribenzyl amine, dimethylbenzyl amine, morpholine, N-methylmorpholine, N,N'-dimethylpiperazine, N-ethylpiperidine, 1,1,5,5-tetramethylpiperidine, 30 dimethylaminopyridine, pyridine, quinoline, tetramethylethylenediamine and the like. Non-limiting

examples of ammonium hydroxides, usually made from amines and water, can include ammonium hydroxide, triethyl ammonium hydroxide, trimethyl ammonium hydroxide, methyldiisopropyl ammonium hydroxide, 5 tribenzyl ammonium hydroxide, dimethylbenzyl ammonium hydroxide, morpholinium hydroxide, N-methylmorpholinium hydroxide, N,N'-dimethylpiperazinium hydroxide, N-ethylpiperidinium hydroxide, and the like. As non-limiting examples, quaternary ammonium hydroxides can 10 include tetraethyl ammonium hydroxide, tetramethyl ammonium hydroxide, dimethyldiisopropyl ammonium hydroxide, benzylmethyldiisopropyl ammonium hydroxide, methyldiazabicyclononyl ammonium hydroxide, methyltribenzyl ammonium hydroxide, N,N- 15 dimethylmorpholinium hydroxide, N,N,N', N',- tetramethylpiperazinium hydroxide, and N-ethyl-N'-hexylpiperidinium hydroxide and the like. Metal hydrides, amide or alcoholates such as calcium hydride, sodium hydride, potassium hydride, lithium hydride, 20 sodium methoxide, potassium tert-butoxide, calcium ethoxide, magnesium ethoxide, sodium amide, potassium diisopropyl amide and the like may also be suitable reagents. Organometallic deprotonating agents such as alkyl or aryl lithium reagents such as methyl, phenyl 25 or butyl lithium, Grignard reagents such as methylmagnesium bromide or methymagnesium chloride, organocadmium reagents such as dimethylcadmium and the like may also serve as bases for causing salt formation or catalyzing the reaction. Quaternary ammonium 30 hydroxides or mixed salts are also useful for aiding


-140-

phase transfer couplings or serving as phase transfer reagents.

The first reaction in Scheme 1 also illustrated the use of a mixed solvent THF/H<sub>2</sub>O. This 5 is one solvent system however others may be useful also. For example, the reaction media can consist of a single solvent, mixed solvents of the same or different classes or serve as a reagent in a single or mixed solvent system. The solvents can be protic, non-protic 10 or dipolar aprotic. Non-limiting examples of protic solvents include water, methanol (MeOH), denatured or pure 95% or absolute ethanol, isopropanol and the like. Typical non-protic solvents include acetone, tetrahydrofuran (THF), dioxane, diethylether (ether), 15 tert-butylmethyl ether (TBME), aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane, heptane, isooctane, cyclohexane and the like. Dipolar aprotic 20 solvents include compounds such as dimethylformamide (DMF), dimethylacetamide (DMAc), acetonitrile, nitromethane, tetramethylurea, N-methylpyrrolidone and the like.

-141-

Scheme 2



Non-limiting examples of ammonium hydroxides,

- 5 usually made from amines and water, can include ammonium hydroxide, triethyl ammonium hydroxide, trimethyl ammonium hydroxide, methyldiisopropyl ammonium hydroxide, tribenzyl ammonium hydroxide, dimethylbenzyl ammonium hydroxide, morpholinium
- 10 hydroxide, N-methylmorpholinium hydroxide, N,N'-dimethylpiperazinium hydroxide, N-ethylpiperidinium hydroxide, and the like. As non-limiting examples, quaternary ammonium hydroxides can include tetraethyl ammonium hydroxide, tetramethyl ammonium hydroxide,
- 15 dimethyldiisopropyl ammonium hydroxide, benzylmethyldiisopropyl ammonium hydroxide, methyldiazabicyclononyl ammonium hydroxide, methyltribenzyl ammonium hydroxide, N,N-dimethylmorpholinium hydroxide, N,N,N',

N',-tetramethylpiperazinium hydroxide, and N-ethyl-N'-hexylpiperidinium hydroxide and the like. Metal hydrides, amide or alcoholates such as calcium hydride, sodium hydride, potassium hydride, lithium hydride, 5 sodium methoxide, potassium tert-butoxide, calcium ethoxide, magnesium ethoxide, sodium amide, potassium diisopropyl amide and the like may also be suitable reagents. Organometallic deprotonating agents such as alkyl or aryl lithium reagents such as methyl, phenyl 10 or butyl lithium, Grignard reagents such as methylmagnesium bromide or methymagnesium chloride, organocadmium reagents such as dimethylcadmium and the like may also serve as bases for causing salt formation or catalyzing the reaction. Quaternary ammonium 15 hydroxides or mixed salts are also useful for aiding phase transfer couplings or serving as phase transfer reagents.

The first reaction in Scheme 1 also illustrated the use of a mixed solvent THF/H<sub>2</sub>O. This is 20 one solvent system however others may be useful also. For example, the reaction media can consist of a single solvent, mixed solvents of the same or different classes or serve as a reagent in a single or mixed solvent system. The solvents can be protic, non-protic 25 or dipolar aprotic. Non-limiting examples of protic solvents include water, methanol (MeOH), denatured or pure 95% or absolute ethanol, isopropanol and the like. Typical non-protic solvents include acetone, tetrahydrofuran (THF), dioxane, diethylether (ether), 30 tert-butylmethyl ether (TBME), aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl

acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane, heptane, isooctane, cyclohexane and the like. Dipolar aprotic solvents include compounds such as dimethylformamide 5 (DMF), dimethylacetamide (DMAc), acetonitrile, nitromethane, tetramethylurea, N-methylpyrrolidone and the like.

Non-limiting examples of reagents that can be used as solvents or as part of a mixed solvent system 10 include organic or inorganic mono- or multi-protic acids or bases such as hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, succinic acid, triethylamine, morpholine, N-methylmorpholine, piperidine, pyrazine, piperazine, 15 pyridine, potassium hydroxide, sodium hydroxide, alcohols, ammonia or amines for making esters or amides and the like.

Acids are used in many reactions during various synthesis. Scheme 1 illustrates acid use for 20 the removal of the THP protecting group to produce the hydroxamic acid of Formula I. The acid might be mono-, di- or tri-protic organic or inorganic acids. Examples of acids include hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, 25 succinic acid, hydrobromic acid, hydrofluoric acid, carbonic acid, phosphorus acid, p-toluene sulfonic acid, trifluoromethane sulfonic acid, trifluoroacetic acid, difluoroacetic acid, benzoic acid, methane sulfonic acid, benzene sulfonic acid, 2,6- 30 dimethylbenzene sulfonic acid, trichloroacetic acid, nitrobenzoic acid, dinitrobenzoic acid, trinitrobenzoic

acid, and the like. They might also be Lewis acids such as aluminum chloride, borontrifluoride, antimony pentafluoride and the like. A preferred solvent in this type reaction is dioxane eith an alcohol or water 5 however almost any solvent system with one component being a protic solvent can be useful.

Scheme I illustrates conversion of a carboxylic acid protected as an ester or amide into an hydroxamic acid derivative such as a O-arylalkylether 10 or O-cycloalkoxyalkylether group. In particular, the this Scheme the protecting group on the hydroxylamine is the THP group. In the case where hydroxylamine is used, treatment of an ester or amide with one or more equivalents of hydroxylamine hydrochloride at room 15 temperature or above in a solvent or solvents, usually protic or partially protic, such as those listed above can provide a hydroxamic acid directly. This exchange process may be further catalyzed by the addition of additional acid. Alternatively, a base such as a salt 20 of an alcohol used as a solvent, for example, sodium methoxide in methanol, can be used to form hydroxylamine from hydroxylamine hydrochloride in situ which can exchange with an ester or amide. As mentioned above, exchange can be carried out with a 25 protected hydroxyl amine such as tetrahydropyranyl-hydroxyamine (THPONH<sub>2</sub>), benzylhydroxylamine (BnONH<sub>2</sub>), and the like in which case compounds such as shown in Scheme 1 that are tetrahydropyranyl (THP) or benzyl (Bn) hydroxamic acid derivatives are the products. 30 Removal of the protecting groups when desired, for example, following further transformations in another

part of the molecule or following storage, is accomplished by standard methods well known in the art such as acid hydrolysis of the THP group as discussed above or reductive removal of the benzyl group with 5 hydrogen and a metal catalyst such as palladium, platinum, palladium on carbon or nickel.

In the case where P is hydrogen, i.e., where the intermediate is a carboxylic acid, standard coupling reactions can be used. For example, the acid 10 can be converted into an acid chloride, mixed anhydride or activated ester and treated with hydroxylamine or a protected hydroxylamine in the presence of a non-competitive base to the nitrogen acylated compound. This is the same product as discussed above. Couplings 15 of this nature are well known in the art and especially the art related to peptide and amino acid chemistry.

Scheme II illustrates another possible synthesis of the compounds of Formula I starting with a protected or unprotected amino acid. Sulfenylation of 20 the amino group is accomplished as discussed above to produce the sulfonamide II-B. This compound is a secondary sulfonamide and, as such, is acidic and can be alkylated with an R<sup>2</sup> group. Alkylation, a process well known in the art, can be carried by treatment of 25 the sulfonamide with base to form the corresponding anion, adding an electrophilic reagent and allowing the SN<sub>2</sub> reaction to proceed. Electrophiles include halogen derivatives, sulfonate esters, epoxides and the like. The bases and solvents discussed with regard to Scheme 30 I are applicable in this Scheme. Preferred bases are those that are hindered such that competition with the

electrophile is minimized. Additional preferred bases are metal hydrides, amide anions or organometallic bases such as a butyl lithium. The solvents, solvent mixtures or solvent/reagent mixtures discussed are 5 satisfactory but non-protic or dipolar aprotic solvents such as acetone, acetonitrile, DMF and the like are examples of preferred classes.

Scheme III illustrates the potential for use of a sulfonyl chloride reagent, specifically 10 nitrobenzenesulfonyl chloride, to prepare compounds of this invention. It should be noted that this reagent is for illustration and is not to be considered limiting or required. After coupling with an amino acid and alkylation of the coupling product if 15 required, the nitrosulfonamide can be reduced to provide a useful amino compound. The amino group can be alkylated if desired. It can also be acylated with an aroyl chloride, heteroaryl or other R<sup>6</sup> amine carbonyl froming agent to form a -C(=O)- or -S(=O)<sub>n</sub>- 20 compound of this invention. The amino sulfonamide can also be reacted with a carbonic acid ester chloride as shown in Scheme IV, a sulfonyl chloride as shown in Scheme V or in Scheme VII or a carbamoyl chloride or isocyanate as shown in Scheme VI to produce the 25 corresponding carbamate, sulfonamides, or ureas of this invention. Acylation of amines of this type are well known in the art and the reagents are also well known. Usually these reactions are carried out in aprotic solvents under an inert or/and dry atmosphere at about 30 45°C to about -10°C. An equivalent of a non-competitive base is usually used with sulfonyl

chloride, acid chloride or carbonyl chloride reagents. Following this acylation step, synthesis of the hydroxamic acid products of this invention can proceed as discussed above for Scheme I and Scheme II.


5           Schemes II through VI also illustrate the possible reduction of a nitrobenzenesulfonamide to produce an amino sulfonamide. The reduction of nitro groups to amines is well known in the art with a preferred method being hydrogenation. There is usually  
10          a metal catalyst such as Rh, Pd, Pt, Ni or the like with or without an additional support such as carbon, barium carbonate and the like. Solvents can be protic or non-protic pure solvents or mixed solvents as required. The reductions can be carried out at  
15          atmospheric pressure to a pressure of multiple atmospheres with atmospheric pressure to about 40 pounds per square inch (psi) preferred.

Other sulfonyl chloride reagents can also be used in the preparation of compounds of this invention  
20          as outlined in the Schemes. Examples are fluoroaryl or fluoroheteroaryl sulfonyl chlorides, azidoaryl or azidoheteroaryl or amide, carbonate, carbamate or urea substituted aryl or heteroaryl sulfonyl chloride reagents. Azides, for example, can be reduced to an  
25          amino group using hydrogen with a metal catalyst or metal chelate catalyst or activated hydride transfer reagent. The fluoro substituted sulfonic acid or sulfonamide can be treated with a nucleophile such as ammonia or a primary amine, under pressure if desired,  
30          to provide an amino or substituted (R5) amino group

-148-


that can then be reacted a reagent as outline in Scheme III and in Schemes 4-7 inclusive.

Scheme III




-149-

Scheme 4




-150-

Scheme 5




Formula V

Scheme 6



Scheme 7



Compounds of the present can possess one or

5 more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or nonracemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional

10 processes well known in the art, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyl tartaric, dibenzoyl tartaric, ditoluoyl tartaric and

15 camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography

20 column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric

molecules, e.g., esters, amides, acetals, ketals, and the like, by reacting compounds of Formula I with an optically active acid in an activated form, a optically active diol or an optically active isocyanate. The

5 synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomericaly pure compound. In some cases hydrolysis to the parent

10 optically active drug is not necessary prior to dosing the patient since the compound can behave as a prodrug. The optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials.

15 Contemplated equivalents of the general formulas set forth above for the MMP inhibitor compounds and derivatives as well as the intermediates are compounds otherwise corresponding thereto and having the same general properties such as tautomers thereof and

20 compounds wherein one or more of the various R groups are simple variations of the substituents as defined therein, e.g., wherein R is a higher alkyl group than that indicated. In addition, where a substituent is designated as, or can be, a hydrogen, the exact chemical

25 nature of a substituent which is other than hydrogen at that position, e.g., a hydrocarbyl radical or a halogen, hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure. For

30 example, two hydroxyl groups, two amino groups, two thiol groups or a mixture of two hydrogen-heteroatom groups on

-154-

the same carbon are known not to be stable without protection or as a derivative.

The chemical reactions described above are generally disclosed in terms of their broadest

- 5 application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art.
- 10 In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine
- 15 modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or
- 20 readily preparable from known starting materials.


Best Mode for Carrying Out the Invention

Without further elaboration, it is believed that one skilled in the art can, using the preceding

- 25 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limiting of the remainder of the disclosure in any way whatsoever.

Example 1. N-hydroxy-2(R)-[[[(4-benzoylamino)-benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanamide, hydrochloride

5



Part A: To a stirred solution of D-valine (10.0g) in a 2:1 mixture of THF/water (200mL)

10 containing 3 equiv. of triethylamine at 5°C is added 4-(benzoylamino)benzenesulfonyl chloride (0.9 equiv.) and the reaction is stirred to room temperature overnight. The resulting mixture is diluted with dichloromethane, and washed with 1N HCl, and water.

15 The organic layer is dried over magnesium sulfate, filtered and concentrated *in vacuo* to provide the desired N-[(4-benzoylamino)benzenesulfonyl]-(D)-valine as a crude product. A solution of the crude acid (10 grams) in 80 mL of dry toluene is charged with

20 dimethylformamide di-*tert*-butylacetal (45 mL) and heated to 100°C for several hours. The resulting cooled solution is concentrated by rotary evaporation and purified by silica gel chromatography to provide

the desired N-[(4-benzoylamino)benzenesulfonyl]-(D)-valine, tert-butyl ester.

Part B: To a dimethylformamide solution (100 mL) of the tert-butyl ester from Part A (5.0 grams) is 5 added 4-(2-chloroethyl)-morpholine hydrochloride (1.3 equivalents) and potassium carbonate (3 equivalents); this suspension is heated to 70°C for five hours. The resulting suspension is cooled and diluted with water (500 mL) and extracted with ethyl acetate. The organic 10 layer is washed with water (2 x 200 mL), saturated sodium bicarbonate (2 x 200mL), and brine, dried over magnesium sulfate, filtered and concentrated to yield the desired product, t-butyl 2(R)-{[(4-benzoylamino)-benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanoate, which can be purified by silica gel 15 chromatography.


Part C: t-Butyl 2(R)-{[(4-benzoylamino)-benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanoate from Part A (4.0 grams) in 100 mL of 20 anhydrous dichloromethane, is cooled to -5°C , and dry HCl gas is bubbled into the reaction flask for 20 minutes. The flask is sealed and allowed to warm to room temperature over three to four hours. The solvent is removed by rotary evaporation and the 25 desired acid, hydrochloride salt, (2(R)-{[(4-benzoylamino)benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanoic acid hydrochloride) is triturated with ether hexane and filtered. The dried precipitate is used without 30 further purification.

Part D: 2(R)-[[(4-benzoylamino)benzene-sulfonyl][(4-ethylmorpholino)amino]-3-methylbutanoic acid hydrochloride from Part C (3.8 grams) and 1-hydroxybenzotriazole (1.5 equivalents) are dissolved in anhydrous dimethylformamide (50 mL) and cooled to 10°C. To this is added N-methylmorpholine (3 equivalents) followed by EDC (1.1 equivalents) and this solution is stirred for two hours at 10°C. To this is added O-tetrahydropyranyl (O-THP) hydroxylamine (2 equivalents) and the solution is stirred overnight at room temperature. The resulting mixture is diluted with 200 mL of water and extracted with ethyl acetate. The organic layer is washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated to yield the desired O-THP-protected hydroxamate, N-tetrahydropyranyloxy-2(R)-[[(4-benzoylamino)-benzenesulfonyl][(4-ethylmorpholino)-amino]-3-methylbutanamide. Further purification by silica gel chromatography provides a mixture of desired diastereomers which are combined.

N-tetrahydropyranyloxy-2(R)-[[(4-benzoylamino)-benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanamide (4.0 grams), is dissolved in a solution of dioxane (150 mL), and ethanol (1mL) and cooled to -5°C. To this is added HCl (5 equivalents; 4N in dioxane) and the solution is stirred for one hour. The contents are concentrated and the desired product is triturated from ether/hexane and filtered to yield the desired N-hydroxy-2(R)-[[(4-benzoylamino)benzenesulfonyl][(4-ethylmorpholino)-amino]-3-methylbutanamide, hydrochloride.

Example 2. N-hydroxy-2(R)-[[[4-benzoylamino)benzene-sulfonyl](3-picollyl)aminolpropanamide

5



Part A: To a solution of D-alanine methyl

10 ester hydrochloride (6.0 grams) in methanol (25 mL) is added 1.1 equivalents of 3-Pyridinecarboxaldehyde. The solution is stirred at room temperature for several hours and then the solvent removed by rotary evaporation. The resulting imine is redissolved in 15 acetic acid (10 mL) and methanol (2 mL), and sodium cyanoborohydride (1.5 equivalents) is added in several portions over 10 minutes. The mixture is then stirred for 16 hours and then concentrated by rotary evaporation. The resulting residue is partitioned 20 between ethyl acetate and aqueous sodium carbonate (10%). The organic layer is dried over magnesium sulfate, filtered and concentrated to yield the desired N-3-picollyl-D-alanine methyl ester.

Part B: To a stirred solution of N-3-

25 picollyl-D-alanine methyl ester (5.0g) in a 2:1 mixture of THF/water (200mL) containing triethylamine (3 equiv.) at 5°C is added 4-(benzoylamino)benzenesulfonyl chloride and the reaction is stirred to room

temperature overnight. The resulting mixture is diluted with dichloromethane, and washed with 1 N HCl, and water. The organic layer is dried over magnesium sulfate, filtered and concentrated *in vacuo* to provide 5 the desired methyl 2(R)-[[[4-benzoylamino)-benzenesulfonyl] [(3-picollyl)amino]propionate as a crude product, which may be purified by silica gel chromatography using ethyl acetate/hexanes as eluant.

Part C: To a solution of methyl ester from 10 Part B (2.0 grams) in tetrahydrofuran (100 mL) is added a solution of aqueous 1N sodium hydroxide (1.2 equiv.) and the reaction mixture is stirred for 20 hours. The solvents are removed by rotary evaporation and the remaining oil is partitioned between ethyl 15 acetate and 1N hydrochloric acid. The organic layer is separated and dried over magnesium sulfate, filtered and concentrated to yield 2(R)-[[[4-benzoylamino)-benzenesulfonyl] [(3-picollyl)amino]propionic acid.


2(R)-[[[4-benzoylamino)benzenesulfonyl]- 20 [(3-picollyl)amino]propionic acid (1.3 grams) and 1-hydroxybenzotriazole (1.5 equivalents) are dissolved in anhydrous dimethylformamide (25 mL) and cooled to 10°C. To this is added N-methylmorpholine (3 equivalents) followed by EDC (1.1 equivalents) and this 25 solution is stirred for two hours at 10°C. To this solution is added O-tetrahydropyranyl hydroxylamine (2 equivalents) and this solution is stirred overnight to room temperature. The solution is diluted with water (100 mL) and extracted with ethyl acetate. The 30 organic layer is washed with saturated sodium bicarbonate and brine, dried over magnesium sulfate,

-160-

filtered and concentrated to yield the desired O-THP protected hydroxamate which is further purified by silica gel chromatography to give a mixture of desired diastereomers which are combined.

5           N-tetrahydropyranloxy-2(R)-[[[(4-benzoylamino)-benzenesulfonyl][(3-picollyl)amino]]-propanamide (1.0 gram), is dissolved in a solution of dioxane (50 mL), and ethanol (1mL) and cooled to -5°C. To this is added 5 equivalents of HCl (4N in dioxane) 10 and the solution is stirred for one hour. The contents are concentrated and the desired product is triturated with ether/hexane and filtered to yield the desired N-hydroxy-2(R)-[[[(4-benzoylamino)benzenesulfonyl][(3-picollyl)amino]]propanamide, hydrochloride. This 15 crude product may be purified by silica gel chromatography using methanol and methylene chloride as the eluant, after neutralization to the free base.

20          Example 3. N-hydroxy-2(R)-[[[(4-(benzenesulfonyl)amino)-benzenesulfonyl][(4-ethylmorpholino)amino]]-3-methylbutanamide, hydrochloride



Part A: To a stirred solution of D-valine (10.0g) in a 2:1 mixture of THF/water (200mL) containing triethylamine (3 equiv.) at 5°C is added 4-nitrobenzene-sulfonyl chloride (0.9 equiv.) and the reaction is stirred at room temperature overnight. The resulting mixture is diluted with dichloromethane, and washed with 1N HCl, and water. The organic layer is dried over magnesium sulfate, filtered and concentrated in vacuo to provide the desired N-(nitrobenzenesulfonyl)-(D)-valine as a crude amino acid product. A solution of the crude amino acid (10 grams) in dry toluene (80 mL) is charged with dimethylformamide di-tertbutylacetal (45 mL) and heated to 100°C for several hours. The resulting cooled solution is concentrated by rotary evaporation and purified by silica gel chromatography to provide the desired N-(4-nitrobenzenesulfonyl)-(D)-valine, tert-butyl ester.

Part B: To a dimethylformamide solution (100 mL) of the tert-butyl ester from Part A (5.0 grams) is added 4-(2-chloroethyl)-morpholine hydrochloride (1.3 equivalents) and potassium carbonate (3 equivalents); and this suspension is heated to 70°C for five hours. The resulting suspension is cooled and diluted with water (500 mL) and extracted with ethyl acetate. The organic layer is washed with water (2 x 200 mL), saturated sodium bicarbonate (2 x 200mL), and brine, dried over magnesium sulfate, filtered and concentrated to yield the desired product, t-butyl 2(R)-[4-

nitrobenzenesulfonyl] [(4-ethylmorpholino)amino]-3-methylbutanoate, which can be purified by silica gel chromatography.

Part C: t-Butyl 2(R)-[4-nitrobenzene-5-sulfonyl] [(4-ethylmorpholino)amino]-3-methylbutanoate (1.5 grams) is added to a Fisher® porter bottle containing ethanol/THF (50 mL each) and 200 mg of 10% palladium on carbon. The bottle is flushed with nitrogen while stirring and then charged with hydrogen at a pressure of 50 psig. After one hour the bottle is flushed with nitrogen and the resulting suspension is filtered through Celite. The filtrate is concentrated to yield t-butyl 2(R)-[4-aminobenzenesulfonyl] [(4-ethylmorpholino)amino]-3-methylbutanoate.

Part D: To a solution of t-butyl 2(R)-[4-aminobenzenesulfonyl] [(4-ethylmorpholino)amino]-3-methylbutanoate from Part C (1.30 grams) in tetrahydrofuran containing N-methylmorpholine (1.2 equivalents) is added benzenesulfonyl chloride (1.0 equivalents); this solution was stirred for 16 hours. The contents were diluted with ethyl acetate and washed with 5% KHSO<sub>4</sub>, saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated to yield the desired t-butyl-2(R)-[[[(4-(benzenesulfonyl)amino)-benzenesulfonyl] [(4-ethylmorpholino)amino]-3-methylbutanoate (1.5 grams).

Part E: t-Butyl-2(R)-[[[(4-(benzenesulfonyl)amino)-benzenesulfonyl] [(4-ethylmorpholino)amino]-3-methylbutanoate from Part D (1.3 grams) in 50 mL of anhydrous dichloromethane is cooled to -5°C, and dry HCl gas is bubbled into the

reaction flask for 20 minutes. The flask is then sealed and allowed to warm to room temperature over three to four hours. The solvent is removed by rotary evaporation and the desired acid, hydrochloride salt is 5 triturated with ether hexane and filtered. The dried precipitate is used without further purification.


t-Butyl-2(R)-[[[(4-(benzenesulfonyl)amino)-benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanoate (1.0 grams) and 1-hydroxybenzotriazole 10 (1.5 equivalents) are dissolved in anhydrous dimethylformamide (25 mL) and cooled to 10°C. To this is added N-methylmorpholine (3 equivalents) followed by EDC (1.1 equivalents) and this solution is stirred for two hours at 10°C. To this solution is added O-tetrahydropyranyl (O-THP) hydroxylamine (2 equivalents); this solution is stirred overnight at room temperature. The solution is diluted with water (100 mL) and extracted with ethyl acetate. The organic layer is washed with saturated sodium bicarbonate and 15 brine, dried over magnesium sulfate, filtered and concentrated to yield the desired O-THP-protected hydroxamate which is further purified by silica gel chromatography to give a mixture of desired diastereomers which are combined.

20 N-tetrahydropyranyloxy-2(R)-[[[(4-(benzenesulfonyl)-amino)benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanoic acid (0.80 grams), is dissolved in a solution of dioxane (20mL), and ethanol (1mL) and cooled to -5°C. To this is added 25 HCl (5 equivalents; 4N in dioxane) and the solution is stirred for one hour. The contents are concentrated

-164-

and the desired product is triturated from ether/hexane and filtered to yield the desired N-hydroxy-2(R)-[[[(4-(benzenesulfonyl)amino)benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanamide,  
5 hydrochloride. This crude product may be purified by silica gel chromatography using methanol and methylene chloride as the eluant, on the free base.

10 Example 4: (R)-N-[4-[[[2-(hydroxyamino)-1-methyl-2-oxoethyl][2-(4-morpholinyl)ethyl]aminosulfonyl]phenyl]benzamide



15

Part A: To a solution of D-alanine, t-butyl ester hydrochloride (9.80 g, 53.9 mmol) in H<sub>2</sub>O (64 mL) and acetone (26 mL) was added triethylamine (17.3 mL, 124 mmol) and the solution was cooled to zero degrees  
20 Celsius. To this solution was added 4-nitrobenzenesulfonyl chloride (11.1 g, 50.2 mmol) dropwise in acetone (25 mL). The solution was stirred for 72 hours. The solution was concentrated in vacuo and the residue was dissolved into ethyl acetate. The  
25 solution was washed with 5% KHSO<sub>4</sub>, saturated NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Recrystallization

(ethyl acetate/hexane) provided the sulfonamide as a solid (10.87 g, 66 %).

Part B: To a solution of the sulfonamide of part A (10.8 g, 32.7 mmol) in DMF (60 mL) was added 5 4-(2-chloroethyl)morpholine (12.2 g, 65.4 mmol) and  $K_2CO_3$  (13.6 g, 98.0 mmol) and the solution was heated to seventy degrees Celsius for 7 hours. The solution was partitioned between ethyl acetate and  $H_2O$ . The organic layer was washed with  $H_2O$ , saturated  $NaCl$  and dried over 10  $Na_2SO_4$ . Concentration in vacuo followed by tritration (ethyl ether) provided the morpholine compound as a solid (8.48 g, 59 %). MS(CI)  $MH^+$  calculated for  $C_{19}H_{29}N_3O_7S$ : 444, found: 444.

Part C: To a solution of the morpholine 15 compound of part B (8.49 g, 19.1 mmol) in THF (100 mL) under atmosphere of 50 psi of hydrogen was added 4% Pd/C and the solution was stirred for 2 hours until uptake stopped. The solution was filtered through Celite and concentration in vacuo of the filtrate 20 provided the aniline as a solid (8.5 g, quantitative yield). MS(CI)  $MH^+$  calculated for  $C_{19}H_{31}N_3O_5S$ : 414, found: 414.

Part D: To a solution of the aniline of part C (2.0 g, 4.8 mmol) in THF (16 mL) was added 25 triethylamine (3.0 mL, 21.3 mmol) and the solution was cooled to zero degrees Celsius. To this solution was added benzoyl chloride (1.46 mL, 12.6 mmol) and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated in vacuo 30 and the residue was partitioned between ethyl acetate and saturated  $NaHCO_3$ . The organic layer was washed with

saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica gel, ethyl acetate/methanol) provided the benzamide as a solid (2.0 g, 80 %). MS(CI) MH<sup>+</sup> calculated for C<sub>26</sub>H<sub>35</sub>N<sub>3</sub>O<sub>6</sub>S: 518, found: 518.


5                   Part E: To a solution of the benzamide of part D (2.0 g, 3.9 mmol) in anisole (9 mL) was added trifluoroacetic acid (26 mL) and the solution was stirred for 18 hours. The solution was concentrated *in vacuo* to remove the trifluoroacetic acid. The 10 remaining solution was poured into ethyl ether and the resulting solid was collect by vacuum filtration to provide the acid as a white solid (1.09 g, 50 %). MS(CI) MH<sup>+</sup> calculated for C<sub>22</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>S: 462, found: 462.

15                   Part F: To a solution of the acid of part E (1.09 g, 1.89 mmol) in methanol (3 mL) cooled to zero degrees Celsius was added thionyl chloride (0.18 mL, 2.4 mmol) and the solution was stirred at ambient temperature for 18 hours. The solution was partitioned between ethyl acetate and saturated NaHCO<sub>3</sub>. The organic 20 layer was washed with saturated NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Reverse phase chromatography (on silica; acetonitrile/H<sub>2</sub>O) provided the methyl ester as a white solid (650 mg, 72 %). MS(CI) MH<sup>+</sup> calculated for C<sub>23</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub>S: 476, found: 476.


25                   Part G: To a solution of the methyl ester of part F (650 mg, 1.4 mmol) in methanol (1.6 mL) and THF (1.6 mL) was added 50% aqueous hydroxylamine (1.6 mL). The solution was stirred for 18 hours. The solution was concentrated *in vacuo* and the residue was 30 partitioned between ethyl acetate and H<sub>2</sub>O. The organic layer was washed with saturated NaCl and dried over

$\text{Na}_2\text{SO}_4$ . Concentration in *vacuo* provided (R)-N-[4-[[2-(hydroxyamino)-1-methyl-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]benzamide as a white solid (380 mg, 58 %). MS(CI)  $\text{MH}^+$  calculated for 5  $\text{C}_{22}\text{H}_{28}\text{N}_4\text{O}_6\text{S}$ : 477, found: 477.

Example 4a: (R)-N-[4-[[2-(hydroxyamino)-1-methyl-2-oxoethyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]benzamide, 10 monohydrochloride



15 To a solution of N-hydroxy-2(R)-[[[(4-




benzoylamino)benzenesulfonyl][(4-ethylmorpholino)amino]-3-methylbutanamide,

-168-

hydrochloride of Example 1 (380 mg, 0.8 mmol) in acetonitrile (30 mL) was added (0.13 mL; 1.59 mmol) 12N HCl and the solution was stirred for 10 minutes. The solution was concentrated in vacuo and the residue was 5 triturated with ethyl ether to provide the hydrochloride salt as a white solid (349 mg, 85 %). MS(CI)  $MH^+$  calculated for  $C_{22}H_{28}N_4O_6S$ : 477, found: 477.

Example 5: (R)-4-bromo-N-[4-[[[2-(hydroxyamino)-1-  
10 methyl-2-oxoethyl] [2-(4-morpholinyl)ethyl]  
amino]sulfonyl]phenyl]benzamide,  
mono(trifluoroacetate) (salt)



15 Part A: To a solution of D-alanine, t-butyl ester hydrochloride (9.80 g, 53.9 mmol) in  $H_2O$  (64 mL) and acetone (26 mL) was added triethylamine (17.3 mL, 124 mmol) and the solution was cooled to zero degrees Celsius. To this solution was added 4-nitrobenzenesulfonyl chloride (11.1 g, 50.2 mmol) dropwise in acetone (25 mL). The solution was stirred for 72 hours. The solution was concentrated in vacuo and the residue was dissolved into ethyl acetate. The solution was washed with 5%  $KHSO_4$ , saturated  $NaHCO_3$ , and saturated  $NaCl$  and dried over  $Na_2SO_4$ . Recrystallization

(ethyl acetate/hexane) provided the sulfonamide as a solid (10.87 g, 66 %).

Part B: To a solution of the sulfonamide of part A (10.8 g, 32.7 mmol) in DMF (60 mL) was added 5 4-(2-chloroethyl)morpholine (12.2 g, 65.4 mmol) and  $K_2CO_3$  (13.6 g, 98.0 mmol) and the solution was heated to seventy degrees Celsius for 7 hours. The solution was partitioned between ethyl acetate and  $H_2O$ . The organic layer was washed with  $H_2O$ , saturated  $NaCl$  and dried over 10  $Na_2SO_4$ . Concentration in *vacuo* followed by titration (ethyl ether) provided the morpholine compound as a solid (8.48 g, 59 %). MS(CI)  $MH^+$  calculated for  $C_{19}H_{29}N_3O_7S$ : 444, found: 444.

Part C: To a solution of the morpholine 15 compound of part B (8.49 g, 19.1 mmol) in THF (100 mL) under atmosphere of 50 psi of hydrogen was added 4% Pd/C and the solution was stirred for 2 hours until uptake stopped. The solution was filtered through Celite and concentration in *vacuo* of the filtrate 20 provided the aniline as a solid (8.5 g, quantitative yield). MS(CI)  $MH^+$  calculated for  $C_{19}H_{31}N_3O_5S$ : 414, found: 414.

Part D: To a solution of the aniline of part 25 C (2.84 g, 6.87 mmol) in THF (40 mL) cooled to zero degrees Celsius was added triethylamine (2.1 mL, 15.1 mmol) followed by 4-bromobenzoyl chloride (1.96 g, 9.93 mmol) in THF (5 mL). The solution was stirred at zero degrees Celsius for 1 hour. The solution was concentrated in *vacuo* and the residue was partitioned 30 between ethyl acetate and saturated  $NaHCO_3$  and the organic is washed with saturated  $NaCl$  and dried over

-170-

$\text{Na}_2\text{SO}_4$ . Chromatography (on silica gel, ethyl acetate/methanol) provided the benzamide as a solid (3.3 g, 81 %). MS(CI)  $\text{MH}^+$  calculated for  $\text{C}_{26}\text{H}_{34}\text{N}_3\text{O}_6\text{SBr}$ : 596, found: 596.

5           Part E: To a solution of the benzamide of part D (2.84 g, 4.76 mmol) in anisole (11 mL) was added trifluoroacetic acid (32 mL) and the solution was stirred at ambient temperature for 18 hours. The solution was concentrated *in vacuo* to remove the  
10 trifluoroacetic acid and the residue was poured into ethyl ether. Filtration provided the acid as an off-white solid (2.8 g, quantitative yield). MS(CI)  $\text{MH}^+$  calculated for  $\text{C}_{22}\text{H}_{26}\text{N}_3\text{O}_6\text{SBr}$ : 541, found 541.

15           Part F: To a solution of the acid of part E (2.71 g, 4.14 mmol) in methanol (10 mL) cooled to zero degrees Celsius was added thionyl chloride (0.38 mL, 5.25 mmol). The solution was stirred for 18 hours at ambient temperature. The solution was partitioned between ethyl acetate and saturated  $\text{NaHCO}_3$  and the  
20 organic layer was washed with saturated  $\text{NaCl}$  and dried over  $\text{Na}_2\text{SO}_4$ . Chromatography (on silica, ethyl acetate/methanol) provided the methyl ester as a solid (1.96 g, 85 %).

25           Part G: To a solution of the methyl ester of part F (1.96 g, 3.53 mmol) in THF (2 mL) and methanol (2 mL) was added 50% aqueous hydroxylamine (4.2 mL, 70.7 mmol) was added and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated *in vacuo* and reverse phase chromatography  
30 (on silica, acetonitrile/ $\text{H}_2\text{O}$  (0.05% TFA)) provided (R)-4-bromo-N-[4-[[[2-(hydroxyamino)-1-methyl-2-


-171-

oxoethyl] [2- (4-morpholinyl)ethyl]amino]sulfonyl] - phenyl]benzamide, mono(trifluoroacetate) salt as a white solid (350 mg, 18 %). MS(EI)  $M^+$  calculated for  $C_{22}H_{27}N_4O_6SBr$ : 555, found: 555.

5

Example 6: (R)-N-[4-[[[2-(hydroxyamino)-1-methyl-2-oxoethyl] [2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]cyclohexanecarboxamide, mono(trifluoroacetate) (salt)

10



Part A: To a solution of D-alanine, t-butyl ester hydrochloride (9.80 g, 53.9 mmol) in  $H_2O$  (64 mL) and acetone (26 mL) was added triethylamine (17.3 mL, 124 mmol) and the solution was cooled to zero degrees Celsius. To this solution was added 4-nitrobenzenesulfonyl chloride (11.1 g, 50.2 mmol) dropwise in acetone (25 mL). The solution was stirred for 72 hours. The solution was concentrated in vacuo and the residue was dissolved into ethyl acetate. The solution was washed with 5%  $KHSO_4$ , saturated  $NaHCO_3$  and saturated  $NaCl$  and dried over  $Na_2SO_4$ . Recrystallization (ethyl

20

acetate/hexane) provided the sulfonamide as a solid (10.87 g, 66 %).

Part B: To a solution of the sulfonamide of part A (10.8 g, 32.7 mmol) in DMF (60 mL) was added 5 4-(2-chloroethyl)morpholine (12.2 g, 65.4 mmol) and  $K_2CO_3$  (13.6 g, 98.0 mmol) and the solution was heated to seventy degrees Celsius for 7 hours. The solution was partitioned between ethyl acetate and  $H_2O$ . The organic layer was washed with  $H_2O$ , saturated  $NaCl$ , and dried 10 over  $Na_2SO_4$ . Concentration in vacuo followed by trituration (ethyl ether) provided the morpholine compound as a solid (8.48 g, 59 %). MS(CI)  $MH^+$  calculated for  $C_{19}H_{29}N_3O_7S$ : 444, found: 444.

Part C: To a solution of the morpholine 15 compound of part B (8.49 g, 19.1 mmol) in THF (100 mL) under atmosphere of 50 psi of hydrogen was added 4% Pd/C and the solution was stirred for 2 hours until uptake stopped. The solution was filtered through Celite and concentration in vacuo of the filtrate 20 provided the aniline as a solid (8.5 g, quantitative yield). MS(CI)  $MH^+$  calculated for  $C_{19}H_{31}N_3O_5S$ : 414, found: 414.

Part D: To a solution of the aniline of part C (2.70 g, 6.53 mmol) in THF (40 mL) was added 25 triethylamine (3.6 mL, 26.1 mmol) and the solution was cooled to zero degrees Celsius. To this solution was added cyclohexane carbonyl chloride (2.3 mL, 17.0 mmol) and the solution was stirred for 30 minutes. The solution was concentrated in vacuo and the residue was 30 partitioned between ethyl acetate and saturated  $NaHCO_3$ . The organic layer was washed with saturated  $NaHCO_3$  and

saturated NaCl, and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/methanol) provided the benzamide as a solid (2.09 g, 61 %). MS(CI) MH<sup>+</sup> calculated for C<sub>26</sub>H<sub>41</sub>N<sub>3</sub>O<sub>6</sub>S: 524, found: 524.


5           Part E: To a solution of the benzamide of part D (2.0 g, 3.82 mmol) in anisole (10 mL) was added trifluoroacetic acid (18 mL). The solution was stirred for 18 hours at ambient temperature. The solution was concentrated *in vacuo* to remove the trifluoroacetic acid. The remaining solution was diluted with ethyl ester and the resulting white solid was collected by vacuum filtration to provide the acid (2.48 g, quantitative yield). MS(CI) MH<sup>+</sup> calculated for C<sub>22</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub>S: 468, found: 468.

15          Part F: To a solution of the acid of part E (1.27 g, 2.18 mmol) in DMF (10 mL) was added N-hydroxybenzotriazole (353 mg, 2.62 mmol) followed by 4-methylmorpholine (1.4 mL, 13.1 mmol), tetrahydropyranyl hydroxylamine (791 mg, 6.76 mmol) and 20 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (590 mg, 3.05 mmol). The solution was stirred for 72 hours. The solution was partitioned between ethyl acetate and saturated NaHCO<sub>3</sub> and the organic was washed with H<sub>2</sub>O and saturated NaCl and dried 25 over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/methanol) provided the ester as a white solid (1.2 g, quantitative yield). MS(CI) MH<sup>+</sup> calculated for C<sub>27</sub>H<sub>42</sub>N<sub>4</sub>O<sub>7</sub>S: 567, found 567.

          Part G: A solution of the ester of part F (1.2 g, 2.12 mmol) in 4N HCl in dioxane (25 mL) was stirred for 1 hour. The solution was diluted with

ethyl ether and resulting white solid was collected by vacuum filtration. The solid was suspended into ethyl acetate and was washed with saturated  $\text{NaHCO}_3$ , and saturated  $\text{NaCl}$  and dried over  $\text{Na}_2\text{SO}_4$ . Reverse phase chromatography (on silica, acetonitrile/ $\text{H}_2\text{O}$ (0.05% TFA)) provided (R)-N-[4-[[[2-(hydroxyamino)-1-methyl-2-oxoethyl] [2-(4-morpholinyl)ethyl]amino]sulfonyl]-phenyl]cyclohexane-carboxamide, mono(trifluoroacetate) salt as a white solid (312 mg, 25 %).  $\text{MS}(\text{CI}) \text{ MH}^+$  calculated for  $\text{C}_{22}\text{H}_{34}\text{N}_4\text{O}_6\text{S}$ : 483, found 483.

Example 7: (R)-N-4-[[[1-[(hydroxyamino)carbonyl]-2-methylpropyl] [2-(4-morpholinyl)ethyl]amino]sulfonyl]-phenyl]-4-propylbenzamide, monohydrochloride



Part A: To a solution to D-valine (25.0 g, 213 mmol) in  $\text{H}_2\text{O}$  (180 mL) and acetone (96 mL) was added triethylamine (62 mL, 448 mmol) and was cooled to zero degrees Celsius. To this solution was added 4-nitrobenzenesulfonyl chloride (45.3 g, 204 mmol) in acetone (100 mL) dropwise. The solution was stirred

for 72 hours. The solution was concentrated *in vacuo* and the resulting aqueous layer was extracted with toluene and acidified to pH = 2 with 2N HCl. The aqueous layer was extracted with ethyl acetate three 5 times and the combined organic layers were washed with saturated NaCl and dried over MgSO<sub>4</sub>. Concentration *in vacuo* provided the sulfonamide as a light brown solid (37.15 g, 61 %).

Part B: A solution of the sulfonamide of 10 part A (37.15 g, 123 mmol) and a catalytic amount of H<sub>2</sub>SO<sub>4</sub> in dichloromethane/dioxane (1L) was subjected to isobutylene for 18 hours. The solution was cooled to zero degrees Celsius and quenched with saturated NaHCO<sub>3</sub>. The aqueous layer was extracted with ethyl acetate and 15 the organic layer was washed with saturated NaCl and dried over MgSO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane) provided the t-butyl ester as a solid (16.7 g, 38 %).

Part C: To a solution of the t-butyl ester 20 of part B (16.5 g, 46 mmol) in DMF (60 mL) was added 4-(2-chloroethyl)morpholine hydrochloride (17.2 g, 92 mmol) and K<sub>2</sub>CO<sub>3</sub> (25.5 g, 184 mmol) and the solution was heated to sixty degrees Celsius for 7 hours. The solution was partitioned between ethyl acetate and H<sub>2</sub>O 25 and the organic layer was washed with saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane) provided the morpholine compound as a solid (21.5 g, 99 %).

Part D: To a solution of the morpholine 30 compound of part C (21.5 g, 45.6 mmol) in THF (200 mL) in a flask purged with H<sub>2</sub> was added 4% Pd/C (3.04 g) and

the solution was hydrogenated until uptake ceased. The solution was filtered through Celite® to remove the excess catalyst and the filtrate was concentrated *in vacuo* to provide the aniline as an oil (19.2 g, 95 %).

5                   Part E: To a solution of the aniline of part D (2.9 g, 6.6 mmol) in THF (20 mL) was added triethylamine (3.66 mL, 26.3 mmol) and cooled to four degrees Celsius. To this solution was added 4-propylbenzoyl chloride (2.0 g, 11.0 mmol) and the 10 solution was stirred for 1 hour at ambient temperature. The solution was concentrated *in vacuo* and the residue was partitioned between ethyl acetate and saturated NaHCO<sub>3</sub>. The organic layer was washed with saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, 15 ethyl acetate/hexane) provided the benzamide as a solid (3.3 g, 85 %).

                 Part F: To a solution of the benzamide of part E (3.2 g, 5.4 mmol) in dichloromethane (20 mL) was added trifluoroacetic acid (80 mL) and the solution was 20 stirred for 30 minutes. The solution was concentrated *in vacuo* and the residue was dissolved into warm toluene/ethyl acetate and was added dropwise to ethyl ether to produce a yellow precipitate. Vacuum filtration provided the acid as a yellow solid (2.58 g, 25 84 %).

                 Part G: To a solution of the acid of part F (2.04 g, 3.6 mmol) in DMF (5 mL) was added N-hydroxybenzotriazole (583 mg, 4.32 mmol), 4-methylmorpholine (2.37 mL, 21.6 mmol), 30 tetrahydropyranyl hydroxylamine (1.31 g, 11.2 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide


-177-

hydrochloride (966 mg, 5.04 mmol). The solution was stirred for 18 hours at ambient temperature. The solution was partitioned between ethyl acetate and saturated  $\text{NaHCO}_3$ . The organic layer was washed with 5 saturated  $\text{NaHCO}_3$ ,  $\text{H}_2\text{O}$  and saturated  $\text{NaCl}$  and dried over  $\text{Na}_2\text{SO}_4$ . Chromatography (on silica, ethyl acetate/methanol) provided the ester as a solid (2.15 g, 95 %).

Part H: Into a solution of the ester of part 10 G (2.15 g, 3.4 mmol) in methanol (30 mL) was bubbled  $\text{HCl}$  gas. After 1 hour the solution was concentrated in vacuo to a reduced volume (5 mL) and this solution was dropped into cooled ethyl ether to produce a precipitate. Vacuum filtration provided (R)-N-4-[[[1- 15 [(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]-phenyl]-4-propylbenzamide, monohydrochloride as a white solid (1.64 g, 83 %). MS(CI)  $\text{MH}^+$  calculated for  $\text{C}_{27}\text{H}_{38}\text{N}_4\text{O}_6\text{S}$ : 547, found 547.

20

Example 8: (R)-4-butyl-N-[4-[[[1-[(hydroxyamino)- 25 carbonyl]-2-methylpropyl][2-(4-morpholinyl)-ethyl]amino]sulfonyl]phenyl]-benzamide monohydrochloride



Part A: To a solution of the aniline of Example 7, part D (2.53 g, 5.73 mmol) in THF (20 mL) was added triethylamine (3.2 mL, 22.9 mmol) and the solution was cooled to four degrees Celsius. To this solution was added 4-butylbenzoyl chloride (1.9 g, 9.7 mmol) and the solution was stirred at ambient temperature for 18 hours. The solution was concentrated *in vacuo* and the residue was partitioned between ethyl acetate and saturated NaHCO<sub>3</sub>. The organic layer was washed with saturated NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane) provided the benzamide as a solid (2.8 g, 82 %).

Part B: A solution of the benzamide of part A (2.8 g, 4.6 mmol) in 4N HCl in dioxane (20 mL) was stirred for 72 hours at ambient temperature. The solution was concentrated *in vacuo* and the residue was dissolved in dioxane (3 mL) and dropped into stirring ethyl ether. The resulting precipitate was collected by vacuum filtration to provide the acid as a white solid (2.7 g, quantitative yield).

Part C: To a solution of the acid of part B (2.0 g, 3.4 mmol) in DMF (5 mL) was added N-

-179-

hydroxybenzotriazole (557 mg, 4.13 mmol) and the solution was cooled to four degrees Celsius. To this solution was added 4-methylmorpholine (2.27 mL, 20.6 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (923 mg, 4.81 mmol) and tetrahydropyranyl hydroxylamine (604 mg, 5.16 mmol) and the solution was stirred for 1 hour. The solution was partitioned between ethyl acetate and saturated  $\text{NaHCO}_3$ . The organic layer was washed with saturated  $\text{NaHCO}_3$ ,  $\text{H}_2\text{O}$  and saturated  $\text{NaCl}$ , and dried over  $\text{Na}_2\text{SO}_4$ . Chromatography (on silica, ethyl acetate/methanol) provided the ester as a solid (2.0 g, 91 %).

Part D: To a solution of the ester of part C (2.0 g, 3.1 mmol) in methanol (1.5 mL) was added 4N HCl in dioxane (10 mL) and the solution was stirred for 18 hours. The solution was concentrated in vacuo to a smaller volume and dropped into ethyl ether. The resulting precipitate was collected by vacuum filtration to provide (R)-4-butyl-N-[4-[[[1-[(hydroxyamino)-carbonyl]-2-methylpropyl][2-(4-morpholinyl)-ethyl]amino]sulfonyl]phenyl]benzamide, monohydrochloride as a white solid (1.8 g, 96 %).


MS(CI)  $\text{MH}^+$  calculated for  $\text{C}_{28}\text{H}_{40}\text{N}_4\text{O}_6\text{S}$ : 561, found: 561.

25

Example 9: R-N-[4-[[[1-(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-orpholinyl)ethyl]amino]-sulfonyl]phenyl]-4-pentylbenzamide, monohydrochloride

30

-180-



Part A: To a solution of the aniline of Example 7, part D (2.60 g, 5.88 mmol) in THF (20 mL) 5 was added triethylamine (3.2 mL, 22.8 mmol) and the solution was cooled to four degrees Celsius. To this solution was added 4-pentylbenzoyl chloride (2.1 g, 10.0 mmol) and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated in 10 vacuo and the residue was partitioned between ethyl acetate and saturated NaHCO<sub>3</sub>. The organic layer was washed with saturated NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (ethyl acetate/hexane) provided the benzamide as a solid (2.09 15 g, 58 %):

Part B: A solution of the benzamide of part A (2.09 g, 3.4 mmol) in 4N HCl (20 mL) was stirred for 72 hours. The solution was concentrated in vacuo and the residue was dissolved into ethyl acetate (5 mL) and 20 dropped into ethyl ether. The resulting precipitate was collected by vacuum filtration to provide the acid as a solid (1.9 g, 94 %).


Part C: To a solution of the acid of part B (1.52 g, 2.56 mmol) in DMF (5 mL) was added 25 N-hydroxybenzotriazole (414 mg, 3.07 mmol) and the

solution was cooled to four degrees Celsius. To this solution was added 4-methylmorpholine (1.69 mL, 15.6 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (687 mg, 3.58 mmol) and tetrahydropyranyl 5 hydroxylamine (449 mg, 3.84 mmol) and was stirred for 1 hour at ambient temperature. The solution was partitioned between ethyl acetate and saturated  $\text{NaHCO}_3$ , and the organic layer was washed with saturated  $\text{NaHCO}_3$ , saturated  $\text{NaCl}$  and  $\text{H}_2\text{O}$  and dried over  $\text{Na}_2\text{SO}_4$ .

10 Chromatography (ethyl acetate/methanol) provided the ester as a solid (1.54 g, 91 %).

Part D: To a solution of the ester of part C (1.54 g, 2.34 mmol) in methanol (1 mL) was added 4N HCl (10 mL) and the solution was stirred for 18 hours at 15 ambient temperature. The solution was concentrated *in vacuo*. Reverse phase chromatography (on silica, acetonitrile/ $\text{H}_2\text{O}$ (HCl) provided the title compound, R-N-[4-[[[1-(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenyl]-4-pentylbenzamide, monohydrochloride, as a white solid (745 mg, 52 %). MS(CI)  $\text{MH}^+$  calculated for  $\text{C}_{29}\text{H}_{42}\text{N}_4\text{O}_6\text{S}$ : 20 575, found: 575.

25 Example 10: (R)-4-hexyl-N-[4-[[[1-(hydroxyamino)-carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]-phenylbenzamide, monohydrochloride



Part A: To a solution of the aniline of Example 7, part D (2.5 g, 5.7 mmol) was added 5 triethylamine (3.2 mL, 22.8 mmol) and the solution was cooled to four degrees Celsius. To this solution was added 4-hexylbenzoyl chloride (2.18 g, 9.69 mmol) and the solution was stirred overnight at ambient temperature. The solution was concentrated *in vacuo* 10 and the residue was partitioned between ethyl acetate and saturated NaHCO<sub>3</sub>. The organic layer was washed with saturated NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane) provided the benzamide as a solid (2.76 15 g, 77 %).

Part B: A solution of the benzamide of part A (2.7 g, 4.3 mmol) in 4N HCl in dioxane (20 mL) was stirred for 72 hours. The solution was concentrated *in vacuo* and the residue was dissolved into ethyl acetate 20 (5 mL). This solution was dropped into ethyl ether. The resulting precipitate was collected by vacuum filtration to provide the acid as a solid (2.5 g, 95 %).

Part C: To a solution of the acid of part B 25 (2.03 g, 3.33 mmol) in DMF (5 mL) was added N-hydroxybenzotriazole (540 mg, 4.00 mmol) and the

solution was cooled to four degrees Celsius. To this solution was added 4-methylmorpholine (2.19 mL, 20.0 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (894 mg, 4.66 mmol) and tetrahydropyranyl hydroxylamine (615 mg, 5.00 mmol) and the solution was stirred for 1 hour at ambient temperature. The solution was partitioned between ethyl acetate and saturated NaHCO<sub>3</sub> and the organic layer was washed with saturated NaHCO<sub>3</sub>, saturated NaCl and H<sub>2</sub>O and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/methanol) provided the ester as a solid (2.01 g, 90 %).

Part D: To a solution of the ester of part C (2.01 g, 3.24 mmol) in methanol (1 mL) was added 4N HCl (10 mL) and the solution was stirred for 18 hours at ambient temperature. Reverse phase chromatography (on silica, acetonitrile/H<sub>2</sub>O(0.05% HCl)) provided the title compound, (R)-4-hexyl-N-[4-[[[1-(hydroxyamino)carbonyl]-2-methylpropyl] [2-(4-morpholinyl)ethyl]amino]sulfonyl]-phenylbenzamide, monohydrochloride, as a white solid (1.23 g, 61 %). MS(CI) MH<sup>+</sup> calculated for C<sub>30</sub>H<sub>44</sub>N<sub>4</sub>O<sub>6</sub>S: 589, found: 589.

25 Example 10a: (R)-4-hexyl-N-[4-[[[1-(hydroxyamino)-carbonyl]-2-methylpropyl] [2-(4-morpholinyl)ethyl]amino]sulfonyl]-phenylbenzamide


30 To a solution of the methyl ester of Example 10, part C (1.4 mmol) in methanol (1.6 mL) and THF (1.6

mL) is added 50% aqueous hydroxylamine (1.6 mL). The solution is stirred for 18 hours. The solution is concentrated in vacuo and the residue was partitioned between ethyl acetate and H<sub>2</sub>O. The organic layer is 5 washed with saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Concentration of the dried organic layer in vacuo provides "10-Hydrochloride. MS(CI) MH<sup>+</sup> calculated for C<sub>30</sub>H<sub>44</sub>N<sub>4</sub>O<sub>6</sub>S: 589.

10

Example 11: (R)-N-[4-[[[1-[(hydroxyamino)carbonyl]-2-methylpropyl](3-pyridinylmethyl)aminosulfonyl]phenyl]-4-propylbenzamide

15



Part A: To a solution of aniline (3.3 g, 35.7 mmol) and triethylamine (8.0 g, 79 mmol) in THF, cooled to zero degrees Celsius, was added benzoyl 20 chloride (5.0 g, 27 mmol) and the solution was stirred for 18 hours at ambient temperature. The solution was diluted with H<sub>2</sub>O and extracted with ethyl acetate. The organic layer was washed with 1N HCl and saturated NaHCO<sub>3</sub>, and dried over MgSO<sub>4</sub>. Recrystallization (ethyl 25 acetate/hexane) provided the benzamide as an off-white solid (4.91 g, 64%).

Part B: To chlorosulfonic acid (2.0 g, 17.3 mmol) cooled to five degrees Celsius was added the benzamide of part A (4.91 mg, 17.3 mmol). The solution was heated to sixty-five degrees Celsius for 1 hour.

5 The solution was cooled to ambient temperature and diluted with dichloromethane. The solution was poured into cold H<sub>2</sub>O and extracted with ethyl acetate. The organic layer was washed with saturated NaHCO<sub>3</sub> and dried over MgSO<sub>4</sub>. Concentration in vacuo provided the 10 sulfonyl chloride as a yellow solid (4.89 g, 74 %).

Part C: To a solution of D-valine, t-butyl ester (2.6 g, 15.1 mmol) in THF (25 mL) was added the sulfonyl chloride of part B (4.8 g, 12.5 mmol) followed by triethylamine (6.3 mL, 44.5 mmol) and the solution 15 was stirred for 18 hours at ambient temperature. The solution was diluted with H<sub>2</sub>O and the resulting precipitate was collected by vacuum filtration. The solid was dissolved into ethyl acetate and dichloromethane and dried over Na<sub>2</sub>SO<sub>4</sub>. Concentration in 20 vacuo provided the sulfonamide (4.0 g, 67 %).

Part D: To a solution the sulfonamide of part C (2.0 g, 4.1 mmol) in DMF (10 mL) was added K<sub>2</sub>CO<sub>3</sub> (2.2 g, 16 mmol) followed by picolyl chloride hydrochloride (860 mg, 5.0 mmol) and the solution was 25 stirred for 40 hours at ambient temperature. The solution was partitioned between ethyl acetate and H<sub>2</sub>O. The organic layer was chromatographed (on silica, ethyl acetate/hexane) to provide the picolyl compound (1.3 g, 57 %).

30 Part E: To a solution of the picolyl compound of part D (1.1 g, 2 mmol) in dichloromethane


(15 mL) was added trifluoroacetic acid (20 mL) and the solution was stirred for 20 minutes. Concentration *in vacuo* provided the acid as a solid (1.24 mg, quantitative yield).

5                   Part F: To a solution of the acid of part E (1.2 g, 2.0 mmol) in DMF (20 mL) was added 4-methylmorpholine (1.2 g, 12 mmol), N-hydroxybenzotriazole (800 mg, 3 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (780 mg, 4 mmol). After 10 minutes of stirring, tetrahydropyranyl hydroxylamine (720 mg, 6 mmol) was added and the solution was stirred for 18 hours. The solution was concentrated *in vacuo* and the residue was partitioned between ethyl acetate and  $\text{H}_2\text{O}$ . The organic 10 layer was dried over  $\text{MgSO}_4$ . Chromatography (on silica, ethyl acetate/hexane/methanol) provided the ester as an 15 oil (1.4 g, quantitative yield).

                 Part G: A solution of the ester of part F (1.4 g, 2 mmol) in dioxane (5 mL) and 4M HCl in dioxane 20 (10 mL) was stirred for 30 minutes. Dilution with ethyl ether which precipitated a white solid followed by collection by vacuum filtration provided the title compound, (R)-N-[4-[[[1-[(hydroxyamino)carbonyl]-2-methylpropyl](3-pyridinylmethyl)amino]sulfonyl]phenyl]-25 4-propylbenzamide (1.28 g, 2.3 mmol). MS(CI)  $\text{MH}^+$  calculated for  $\text{C}_{27}\text{H}_{32}\text{N}_4\text{O}_5\text{S}$ : 525, found: 525.

Example 12: (R)-N-[4-[[[1-(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]-amino]sulfonyl]phenyl]benzamide, monohydrochloride

5



Part A: To a solution of the aniline of Example 7, part D (2.2 g, 5.0 mmol) in dichloromethane (5 mL) was added triethylamine (1.0 g, 10 mmol) and the 10 solution was cooled to zero degrees Celsius. To this solution was added benzoyl chloride (717 mg, 5.1 mmol) in dichloromethane (5 mL). The solution was stirred for 16 hours at ambient temperature. The solution was diluted with dichloromethane and washed with saturated 15 NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane) provided the benzamide as a solid (2.7 g, 99 %).

Part B: To a solution of the benzamide of part A (2.56 g, 4.69 mmol) in dichloromethane (50 mL) 20 was added trifluoroacetic acid (12 mL) and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated *in vacuo*. Chromatography (on silica, ethyl acetate/methanol) provided the acid as a solid (1.64 g, 71 %).

-188-


Part C: To a solution of the acid of part C (1.24 g, 2.53 mmol) in DMF (15 mL) was added N-hydroxybenzotriazole (513 mg, 3.8 mmol) and 4-methylmorpholine (1.5 g, 15.2 mmol) and the solution 5 was cooled to zero degrees Celsius. To this solution was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (534 mg, 2.78 mmol) and tetrahydropyranyl hydroxylamine (444 mg, 3.8 mmol) and the solution was stirred for 18 hours at ambient temperature. The 10 solution was diluted with H<sub>2</sub>O and the solution was extracted with ethyl acetate. The organic layer was washed with saturated NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane/methanol) provided the ester as a solid 15 (815 mg, 55 %).

Part D: To a solution of the ester of part C (750 mg, 1.27 mmol) in dioxane (5 mL) was added 4N HCl in dioxane (10 mL) and the solution was stirred for 20 minutes at ambient temperature. Trituration (hexane) 20 provided the title compound, (R)-N-[4-[[[1-(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]-amino]sulfonyl]phenyl]benzamide, monohydrochloride, as a white solid (590 mg, 86 %). MS(CI) MH<sup>+</sup> calculated for C<sub>24</sub>H<sub>32</sub>N<sub>4</sub>O<sub>6</sub>S: 505, found: 505.

25

Example 13: (R)-4-bromo-N-[4-[[[1-(hydroxyamino)-carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]-phenylbenzamide, monohydrochloride

30



Part A: To a solution of the aniline of Example 7, part D (2.2 g, 5 mmol) in dichloromethane (50 mL) was added triethylamine (1.5 g, 15 mmol) and 4-bromobenzoyl chloride (1.65 g, 7.5 mmol) and the solution was stirred for 12 hours at ambient temperature. The solution was diluted with dichloromethane and washed with saturated  $\text{NaHCO}_3$  and saturated  $\text{NaCl}$  and dried over  $\text{Na}_2\text{SO}_4$ . Chromatography (on silica, ethyl acetate/hexane) provided the benzamide as a solid (2.8 g, 90 %).

Part B: To a solution of the benzamide of part A (2.5 g, 4.0 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (16 mL) and the solution was stirred for 16 hours at ambient temperature. The solution was concentrated in vacuo and chromatography (on silica, ethyl acetate/methanol) provided the acid as a solid (1.68 g, 74 %).

Part C: To a solution of the acid of part B (1.2 g, 2.11 mmol) in DMF (20 mL) was added N-hydroxybenzotriazole (428 mg, 3.16 mmol) and 4-methylmorpholine (1.3 g, 12.7 mmol) and the solution was cooled to zero degrees Celsius. To this solution was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (445 mg, 2.32 mmol) and tetrahydropyranyl


-190-

hydroxylamine (371 mg, 3.16 mmol) and the solution was stirred for 18 hours at ambient temperature. The solution was diluted with H<sub>2</sub>O and the solution was extracted with ethyl acetate. The organic layer was 5 washed with saturated NaHCO<sub>3</sub> and saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane/methanol) provided the ester as a solid (940 mg, 67 %).

Part D: To a solution of the ester of part C 10 (800 mg, 1.2 mmol) in dioxane (5 mL) was added 4N HCl in dioxane (10 mL) and the solution was stirred for 20 minutes at ambient temperature. Trituration (hexane) provided the title compound, (R)-4-bromo-N-[4-[[[1-(hydroxyamino)carbonyl]-2-methylpropyl][2-(4-morpholinyl)ethyl]amino]sulfonyl]phenylbenzamide, 15 monohydrochloride, as a white solid (668 mg, 90 %). MS(CI) MH<sup>+</sup> calculated for C<sub>24</sub>H<sub>31</sub>N<sub>4</sub>O<sub>6</sub>SBr: 584, found: 584.

20

Example 14: (R)-N-hydroxy- $\alpha$ -[[4-(4-pentylbenzoyl)-amino]phenyl]sulfonyl]aminobenzenepropanamide



25

-191-

Part A: To a solution of aniline (3.3 g, 35.7 mmol) and triethylamine (8.0 g, 79 mmol) in THF, cooled to zero degrees Celsius, was added 4-pentylbenzoyl chloride (5.7 g, 27 mmol) and the solution was stirred 5 for 18 hours at ambient temperature. The solution was diluted with H<sub>2</sub>O and extracted with ethyl acetate. The organic layer was washed with 1N HCl and saturated NaHCO<sub>3</sub> and dried over MgSO<sub>4</sub>. Recrystallization (ethyl acetate/hexane) provided the benzamide as an off-white 10 solid.

Part B: To chlorosulfonic acid (2.3 g, 20 mmol) cooled to five degrees Celsius was added the benzamide of part A. The solution was heated to sixty-five degrees Celsius for 1 hour. The solution was cooled to 15 ambient temperature and diluted with dichloromethane. The solution was poured into cold H<sub>2</sub>O and extracted with ethyl acetate. The organic layer was washed with saturated NaHCO<sub>3</sub> and dried over MgSO<sub>4</sub>. Concentration in vacuo provided the sulfonyl chloride as a yellow solid 20 (5.5 g, 55 %, two steps).

Part C: To a solution of R-phenylalanine (2.47 g, 15 mmol) in THF (100 mL) and H<sub>2</sub>O (30 mL) cooled to zero degrees Celsius was added triethylamine (4.54 g, 45 mmol) and the sulfonyl chloride of part B (5.5 g, 15 25 mmol) and the solution was stirred for 16 hours at ambient temperature. The solution was concentrated in vacuo and extracted with ethyl acetate. The organic layer was washed with saturated NaCl. Chromatography (on silica, ethyl acetate/hexane) provided the 30 sulfonamide as a solid (4.5 g, 61 %).

-192-


Part D: To a solution of the sulfonamide of part C (494 mg, 1.0 mmol) in DMF (20 mL) was added N-hydroxybenzotriazole (203 mg, 1.5 mmol) and the solution was cooled to ten degrees Celsius. To this 5 solution was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (211 mg, 1.1 mmol) and tetrahydropyranyl hydroxylamine (351 mg, 3.0 mmol) and the solution was stirred for 12 hours at ambient 10 temperature. The solution was diluted with H<sub>2</sub>O and the resulting precipitate was extracted with ethyl acetate and washed with saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (ethyl acetate/hexane) provided the ester as a solid (327 mg, 57 %).

Part E: To a solution of the ester of part D 15 (200 mg, 0.34 mmol) in dioxane (3 mL) was added 4N HCl in dioxane (5 mL) and the solution was stirred for 1 hour at ambient temperature. The solution was concentrated in vacuo and reverse phase chromatography (acetonitrile/H<sub>2</sub>O) provided the title compound, (R)-N- 20 hydroxy- $\alpha$ -[[[4-(4-pentylbenzoyl)amino]phenyl]-sulfonyl]amino benzenepropanamide, as a white solid (80 mg, 26 %). MS(CI) MH<sup>+</sup> calculated for C<sub>27</sub>H<sub>31</sub>N<sub>3</sub>O<sub>5</sub>S: 510, found: 510.

25

Example 15: (R)-N-hydroxy- $\alpha$ -[[2-(4-morpholinyl)ethyl]-[[4-[(4-pentylbenzoyl)amino]phenyl]-sulfonyl]amino]benzenepropanamide, monohydrochloride

-193-



Part A: To a solution of the sulfonamide of Example 14, part C (7.0 g, 15 mmol) in toluene (120 mL) was added DMF di-tert-butylacetal (6.1 g, 30 mmol) and 5 the solution was heated at one hundred degrees Celsius for 1 hour. Concentration *in vacuo* followed by recrystallization (cold methanol) provided the ester as a solid (3.7 g, 45 %).

Part B: To a solution of the ester of part A 10 (3.5 g, 6.35 mmol) and K<sub>2</sub>CO<sub>3</sub> (5.53 g, 40 mmol) in DMF (100 mL) was added 4-(2-chloroethyl)morpholine hydrochloride (1.77 g, 9.52 mmol) and the solution was stirred for 16 hours at sixty degrees Celsius. The solution was partitioned between ethyl acetate and H<sub>2</sub>O 15 and the organic layer was washed with saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (ethyl acetate/hexane) provided the morpholine compound as a solid (1.8 g, 43 %).

Part C: To a solution of the morpholine 20 compound of part B (1.4 g, 2.1 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (12 mL) and the solution was stirred for 16 hours at ambient temperature. Concentration *in vacuo* followed by

-194-

reverse phase chromatography (acetonitrile/H<sub>2</sub>O) provided the acid as a solid (1.12 g, 87 %).

Part D: To a solution of the acid of part C (607 mg, 1.0 mmol) in DMF (40 mL) was added N-hydroxybenzotriazole (207 mg, 1.5 mmol) and the solution was cooled to two degrees Celsius. To this solution was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (211 mg, 1.1 mmol) and tetrahydropyranyl hydroxylamine (585 mg, 5.0 mmol) and the solution was stirred for 6 hours at ambient temperature. The solution was diluted with H<sub>2</sub>O and the resulting precipitate was extracted with ethyl acetate and washed with saturated NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. Chromatography (on silica, ethyl acetate/hexane) provided the ester as a solid.

Part E: To a solution of the ester of part D in dioxane (3 mL) was added 4N HCl in dioxane (5 mL) and the solution was stirred for 1 hour at ambient temperature. The solution was concentrated in vacuo and reverse phase chromatography (acetonitrile/H<sub>2</sub>O) provided the title compound, (R)-N-hydroxy- $\alpha$ -[[2-(4-morpholinyl)ethyl]-[[4-[(4-pentylbenzoyl)amino]phenyl]-sulfonyl]amino]benzenepropanamide, monohydrochloride, as a white solid (80 mg, 12 %, two steps). MS(CI) MH<sup>+</sup> calculated for C<sub>33</sub>H<sub>42</sub>N<sub>4</sub>O<sub>6</sub>S: 660, found: 660.

Example 16: In Vitro Metalloprotease Inhibition

The compounds prepared in the manner described in Examples 1 to 15 were assayed for activity

by an in vitro assay. Following the procedures of Knight et al., FEBS Lett. 296(3):263 (1992). Briefly, 4-aminophenylmercuric acetate (APMA) or trypsin activated MMPs were incubated with various 5 concentrations of the inhibitor compound at room temperature for 5 minutes.

More specifically, recombinant human MMP-13 and MMP-1 enzymes were prepared in laboratories of the assignee. MMP-13 was expressed in baculovirus as a 10 proenzyme, and purified first over a heparin agarose column and then over a chelating zinc chloride column. The proenzyme was activated by APMA for use in the assay. MMP-1 expressed in transfected HT-1080 cells was provided by Dr. Howard Welgus of Washington 15 University, St. Louis, MO. The enzyme was also activated using APMA and was then purified over a hydroxamic acid column.

The enzyme substrate is a methoxycoumarin-containing polypeptide having the following sequence:

20 MCA-ProLeuGlyLeuDpaAlaArgNH<sup>2</sup>, wherein MCA is methoxycoumarin and Dpa is 3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl alanine. This substrate is commercially available from Baychem as product M-1895.

25 The buffer used for assays contained 100 mM Tris-HCl, 100 mM NaCl, 10 mM CaCl<sub>2</sub> and 0.05 percent polyethyleneglycol (23) lauryl ether at a pH value of 7.5. Assays were carried out at room temperature, and dimethyl sulfoxide (DMSO) at a final concentration of 1 percent was used to dissolve inhibitor compound.

30 The assayed inhibitor compound in DMSO/buffer solution was compared to an equal amount of DMSO/buffer

with no inhibitor as control using Microfluor™ White Plates (Dynatech). The inhibitor or control solution was maintained in the plate for 10 minutes and the substrate was added to provide a final concentration of 5 4  $\mu$ M.

In the absence of inhibitor activity, a fluorogenic peptide was cleaved at the gly-leu peptide bond, separating the highly fluorogenic peptide from a 2,4-dinitrophenyl quencher, resulting in an increase of 10 fluorescence intensity (excitation at 328 nm/emission at 415 nm). Inhibition was measured as a reduction in fluorescent intensity as a function of inhibitor concentration, using a Perkin Elmer L550 plate reader. The IC<sub>50</sub> values were calculated from those values. The 15 results are set forth in the Inhibition Table below as Table 9, reported in terms of IC<sub>50</sub>.

-197-

Table 9

## INHIBITION TABLE

Example	hMMP-1 (nM)	hMMP-2 (nM)	hMMP-3 (nM)	hMMP-8 (nM)	hMMP-9 (nM)	hMMP-13 (nM)
4	>10,000				20.0	2.5
4a	>10,000	0.2			24.0	2.2
5	4,850					0.35
6	>10,000				3,500	250
7	4,000	0.2	90.0	9.0	4.5	0.3
8	4,000	0.2	50.0	25.8	31.0	0.1
9	4,000	<0.1	55.0	8.0	200	<0.1
10	5,600				350	<0.1
10a		<0.1	180	2.6		
11	>10,000	0.1	225	39.0	24.0	0.5
12	3,400		800	12.3	245	11.4
13	880				1.9	0.4
14	>10,000	<0.1	30.0	34.0	161	<0.1
15	>10,000	<0.1	140	241	286	<0.1

5

Example 17: In Vivo Angiogenesis Assay

The study of angiogenesis depends on a reliable and reproducible model for the stimulation and inhibition of a neovascular response. The corneal micropocket assay provides such a model of angiogenesis in the cornea of a mouse. See, *A Model of Angiogenesis in the Mouse Cornea*; Kenyon, BM, et al., *Investigative*

-198-

Ophthalmology & Visual Science, July 1996, Vol. 37,  
No. 8.

In this assay, uniformly sized Hydron™ pellets containing bFGF and sucralfate are prepared and 5 surgically implanted into the stroma mouse cornea adjacent to the temporal limbus. The pellets are formed by making a suspension of 20 µL sterile saline containing 10 µg recombinant bFGF, 10 mg of sucralfate and 10 µL of 12 percent Hydron™ in ethanol. The slurry 10 is then deposited on a 10 x 10 mm piece of sterile nylon mesh. After drying, the nylon fibers of the mesh are separated to release the pellets.

The corneal pocket is made by anesthetizing a 7 week old C57Bl/6 female mouse, then proptosing the 15 eye with a jeweler's forceps. Using a dissecting microscope, a central, intrastromal linear keratotomy of approximately 0.6 mm in length is performed with a #15 surgical blade, parallel to the insertion of the lateral rectus muscle. Using a modified cataract 20 knife, a lamellar micropocket is dissected toward the temporal limbus. The pocket is extended to within 1.0 mm of the temporal limbus. A single pellet is placed on the corneal surface at the base of the pocket with a jeweler's forceps. The pellet is then advanced to the 25 temporal end of the pocket. Antibiotic ointment is then applied to the eye.

Mice are dosed on a daily basis for the duration of the assay. Dosing of the animals is based on bioavailability and overall potency of the compound. 30 an exemplary dose is 50 mg/kg bid, po.

Neovascularization of the corneal stroma begins at

about day three and is permitted to continue under the influence of the assayed compound until day five. At day five, the degree of angiogenic inhibition is scored by viewing the neovascular progression with a slit lamp 5 microscope.

The mice are anesthetized and the studied eye is once again proptosed. The maximum vessel length of neovascularization, extending from the limbal vascular plexus toward the pellet is measured. In addition, the 10 contiguous circumferential zone of neovascularization is measured as clock hours, where 30 degrees of arc equals one clock hour. The area of angiogenesis is calculated as follows.

$$area = \frac{(0.4 \times \text{clock hours} \times 3.14 \times \text{vessel length (in mm)})}{2}$$

15

The studied mice are thereafter compared to control mice and the difference in the area of neovascularization is recorded. A contemplated 20 compound typically exhibits about 25 to about 75 percent inhibition, whereas the vehicle control exhibits zero percent inhibition.

Without further elaboration, it is believed 25 that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The foregoing specific embodiments are, therefore, to be construed as merely illustrative, and

-200-

not limitative of the remainder of the disclosure in any way whatsoever.


From the forgoing description, one skilled in the art can easily ascertain the essential 5 characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

-201-

What is Claimed is:

## 1. A compound of formula VII

5



wherein:

n is zero, 1 or 2;

10 W is independently selected from the group consisting of  $-\text{NR}_5\text{COR}_6$ ,  $-\text{NR}_5\text{S(O)}_z\text{R}_7$  where z is zero, 1, or 2,  $-\text{NR}_5\text{COOR}_8$ ,  $-\text{NR}_5\text{CONR}_8\text{R}_9$ , and  $-\text{NR}^{11}\text{R}^{12}$ ;

$\text{R}^1$  is cycloalkylene, arylene or heteroarylene;

15  $\text{R}^2$  is selected from the group consisting of a hydrido, alkyl, aralkyl, heteroaralkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, alkylthioalkyl, hydroxycarbonylalkyl, aroylalkyl, and heteroaroylalkyl group,  $-(\text{CH}_2)_x\text{NR}^{11}\text{R}^{12}$ , or  $-(\text{CH}_2)_x$ -

20  $\text{C(O)}-\text{NR}^{11}\text{R}^{12}$  wherein x is an integer from zero to 6;

$\text{R}^3$  is selected from the group consisting of a hydrido, alkyl, aryl, aralkyl, thioalkyl, heteroaralkyl, heteroaryl, alkoxyalkoxyalkyl, trifluoromethylalkyl, alkoxy carbonylalkyl, 25 aralkoxycarbonylalkyl, hydroxycarbonylalkyl, alkoxyalkyl, heterocycloalkylalkyl, aryloxyalkyl,

alkylthioalkyl, arylthioalkyl, heteroarylthioalkyl group, or a sulfoxide or sulfone of any of said thio-containing groups, a  $-(CH_2)_x-C(O)NR^{11}R^{12}$  group, wherein x is an integer from zero to 6, and a  $-(CH_2)_y-W$  group,  
5 wherein y is an integer from 1 to 6 and W is defined above;  
or R<sup>2</sup> and R<sup>3</sup> together with the atom chain to which they are attached form a 3-8 membered ring;  
10 R<sup>4</sup> is a hydrido or C<sub>1</sub>-C<sub>4</sub> alkyl group;  
R<sup>5</sup> is a hydrido or C<sub>1</sub>-C<sub>4</sub> alkyl group;  
R<sup>6</sup> is selected from the group consisting of a hydrido, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkylalkyl,  
15 heterocycloalkylalkyl, alkoxyalkyl, alkylthioalkyl group, and a  $-(CH_2)_x-NR^{11}R^{12}$  group wherein x is an integer from zero to 6, wherein an aryl or heteroaryl group of R<sup>6</sup> is optionally substituted with one or more substituents independently selected from the group  
consisting of a halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, nitro, cyano, hydroxy, carboxy, hydroxycarbonylalkyl,  
20  $-(CH_2)_x-NR^{11}R^{12}$ , wherein x is an integer from zero to 6, trifluoromethyl, alkoxy carbonyl, aminocarbonyl, thio, alkylsulfonyl, carbonylamino, aminosulfonyl,  
25 alkylsulfonamino, alkoxyalkyl, cycloalkyloxy, alkylthioalkyl and alkylthio group;  
or R<sup>5</sup> and R<sup>6</sup> together with the atom chain to which they are bonded form a 5- to 7-membered a cyclic amide or imide that is substituted or  
30 unsubstituted;

-203-

R<sup>7</sup> is selected from the group consisting of R<sup>6</sup> and alkyl; or R<sup>5</sup> and R<sup>7</sup> together with the atom chain to which they are bonded form a 5- to 7-membered a cyclic sulfonamide that is substituted or

5 unsubstituted;

R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of R<sup>6</sup> and alkyl; or R<sup>8</sup> and R<sup>9</sup> together with the depicted nitrogen atom form a 5- to 7-membered ring containing zero or one heteroatom that is oxygen, 10 nitrogen or sulfur;

R<sup>11</sup> and R<sup>12</sup> are independently selected from the group consisting of a hydrido, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, alkanoyl, aralkanoyl, and heteroaralkanoyl group; or 15 R<sup>11</sup> and R<sup>12</sup> taken together form a 5 to 8-membered heterocyclo or heteroaryl ring;

R<sup>13</sup> is a hydrido or C<sub>1</sub>-C<sub>6</sub> alkyl group; and

R<sup>14</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, substituted aryl, arylalkyl or substituted arylalkyl.

20

2. The compound according to claim 1 wherein n is 2.

25 R<sup>1</sup> is arylene.


4. The compound according to claim 1 wherein w is -NR<sup>5</sup>COR<sup>6</sup>.

-204-

5. The compound according to claim 1 wherein  
W is  $-\text{NR}^5\text{S}(\text{O})_z\text{R}^7$ .

6. The compound according to claim 1 wherein  
5 W is  $-\text{NR}^5\text{COOR}^7$ .

7. A compound of formula I



10

wherein:

n is zero, 1 or 2;

W is independently selected from the group  
consisting of  $-\text{NR}^5\text{COR}^6$ ,  $-\text{NR}^5\text{S}(\text{O})_z\text{R}^7$  where z is zero, 1,  
15 or 2,  $-\text{NR}^5\text{COOR}^8$ ,  $-\text{NR}^5\text{CONR}^8\text{R}^9$ , and  $-\text{NR}^{11}\text{R}^{12}$ ;

$\text{R}^1$  is cycloalkylene, arylene or  
heteroarylene;

20  $\text{R}^2$  is selected from the group consisting of a  
hydrido, alkyl, aralkyl, heteroaralkyl,  
 $\text{R}^3$  cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl,  
alkylthioalkyl, hydroxycarbonylalkyl, aroylalkyl, and  
heteroaroylalkyl group,  $-(\text{CH}_2)_x\text{-NR}^{11}\text{R}^{12}$ , or  $-(\text{CH}_2)_x\text{-}$   
C(O)- $\text{NR}^{11}\text{R}^{12}$  wherein x is an integer from zero to 6;

25  $\text{R}^3$  is selected from the group consisting of a  
hydrido, alkyl, aryl, aralkyl, thioalkyl,  
heteroaralkyl, heteroaryl, alkoxyalkoxyalkyl,

trifluoromethylalkyl, alkoxycarbonylalkyl,  
aralkoxycarbonylalkyl, hydroxycarbonylalkyl,  
alkoxyalkyl, heterocycloalkylalkyl, aryloxyalkyl,  
alkylthioalkyl, arylthioalkyl, heteroarylthioalkyl  
5 group, or a sulfoxide or sulfone of any of said thio-  
containing groups, a  $-(CH_2)_x-C(O)NR^{11}R^{12}$  group, wherein  
x is an integer from zero to 6, and a  $-(CH_2)_y-W$  group,  
wherein y is an integer from 1 to 6 and W is defined  
above;

10 or R<sup>2</sup> and R<sup>3</sup> together with the atom  
chain to which they are attached form a 3-8 membered  
ring;

R<sup>4</sup> is a hydrido or C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>5</sup> is a hydrido or C<sub>1</sub>-C<sub>4</sub> alkyl group;

15 R<sup>6</sup> is selected from the group consisting of a  
hydrido, cycloalkyl, heterocycloalkyl, aryl,  
heteroaryl, aralkyl, heteroaralkyl, cycloalkylalkyl,  
heterocycloalkylalkyl, alkoxyalkyl, alkylthioalkyl  
group, and a  $-(CH_2)_x-NR^{11}R^{12}$  group wherein x is an  
20 integer from zero to 6, wherein an aryl or heteroaryl  
group of R<sup>6</sup> is optionally substituted with one or more  
substituents independently selected from the group  
consisting of a halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, nitro,  
cyano, hydroxy, carboxy, hydroxycarbonylalkyl,  
25  $-(CH_2)_x-NR^{11}R^{12}$ , wherein x is an integer from zero to  
6, trifluoromethyl, alkoxycarbonyl, aminocarbonyl,  
thio, alkylsulfonyl, carbonylamino, aminosulfonyl,  
alkylsulfonamino, alkoxyalkyl, cycloalkyloxy,  
alkylthioalkyl and alkylthio group;

or R5 and R6 together with the atom chain to which they are bonded form a 5- to 7-membered a cyclic amide or imide that is substituted or unsubstituted;

5 R<sup>7</sup> is selected from the group consisting of R<sup>6</sup> and alkyl; or R<sup>5</sup> and R<sup>7</sup> together with the atom chain to which they are bonded form a 5- to 7-membered a cyclic sulfonamide that is substituted or unsubstituted;

10 R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of R<sup>6</sup> and alkyl, or R<sup>8</sup> and R<sup>9</sup> together with the depicted nitrogen atom form a 5- to 7-membered ring containing zero or one heteroatom that is oxygen, nitrogen or sulfur;

15 R<sup>11</sup> and R<sup>12</sup> are independently selected from the group consisting of a hydrido, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, alkanoyl, aralkanoyl, and heteroaralkanoyl group, or R<sup>11</sup> and R<sup>12</sup> taken together form a 5 to 8-membered

20 heterocyclo or heteroaryl ring; and

R<sup>13</sup> is a hydrido or C<sub>1</sub>-C<sub>6</sub> alkyl group.

8. The compound according to claim 7 wherein n is 2.

25


9. The compound according to claim 8 wherein R<sup>1</sup> is arylene.

10. The compound according to claim 9  
30 wherein R<sup>4</sup> is hydrido.

-207-

11. The compound according to claim 7  
wherein W is -NR<sup>5</sup>COR<sup>6</sup>.

5 12. The compound according to claim 7 that  
corresponds in structure to formula III



10 wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup> and R<sup>13</sup> are  
defined above.


13. The compound according to claim 12  
wherein R<sup>6</sup> and R<sup>4</sup> are both hydrido.

15 14. The compound according to claim 13  
wherein R<sup>3</sup> is heterocycloalkylalkyl.

20 15. The compound according to claim 14  
wherein R<sup>6</sup> is aryl.

-208-


16. The compound according to claim 15  
corresponding in structure to the formula



5

17. The compound according to claim 14  
wherein R<sup>6</sup> is heteroarylaryl.


18. The compound according to claim 15  
10 corresponding in structure to the formula



19. The compound according to claim 7  
wherein W is -NR<sup>5</sup>S(O)<sub>z</sub>R<sup>7</sup> where z is 2.


15 20. The compound according to claim 7 that  
corresponds in structure to formula V

-209-




wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>7</sup> and R<sup>13</sup> are defined above.

5 21. The compound according to claim 18 that corresponds in structure to the formula



10 22. A process for treating a host mammal having a condition associated with pathological matrix metalloprotease activity that comprises administering a compound corresponding in structure to Formula I in an MMP enzyme-inhibiting effective amount to a mammalian 15 host having such a condition:



wherein:

n is zero, 1 or 2;

5 W is independently selected from the group consisting of  $-\text{NR}^5\text{COR}^6$ ,  $-\text{NR}^5\text{S(O)}_z\text{R}^7$  where z is zero, 1, or 2,  $-\text{NR}^5\text{COOR}^8$ ,  $-\text{NR}^5\text{CONR}^8\text{R}^9$ , and  $-\text{NR}^{11}\text{R}^{12}$ ;

R<sup>1</sup> is cycloalkylene, arylene or heteroarylene;

10 R<sup>2</sup> is selected from the group consisting of a hydrido, alkyl, aralkyl, heteroaralkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, alkylthioalkyl, hydroxycarbonylalkyl, aroylalkyl, heteroaroylalkyl,  $-(\text{CH}_2)_x\text{-NR}^{11}\text{R}^{12}$ , and  $-(\text{CH}_2)_x\text{-C(O)}$ -

15 NR<sup>11</sup>R<sup>12</sup> group, wherein x is an integer from zero to 6;

R<sup>3</sup> is selected from the group consisting of a hydrido, alkyl, aryl, aralkyl, thioalkyl, heteroaralkyl, heteroaryl, alkoxyalkoxyalkyl, trifluoromethylalkyl, alkoxy carbonylalkyl,

20 aralkoxy carbonylalkyl, hydroxycarbonylalkyl, alkoxyalkyl, heterocycloalkylalkyl, aryloxyalkyl, alkylthioalkyl, arylthioalkyl, heteroarylthioalkyl group, or a sulfoxide or sulfone of any of said thio-containing groups, a  $-(\text{CH}_2)_x\text{-C(O)}\text{NR}^{11}\text{R}^{12}$  group, wherein

25 x is an integer from zero to 6, and a  $-(\text{CH}_2)_y\text{-W}$  group,

wherein y is an integer from 1 to 6 and W is defined above;

or R<sup>2</sup> and R<sup>3</sup> together with the atom chain to which they are attached form a 3-8 membered 5 ring;

R<sup>4</sup> is a hydrido or C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>5</sup> is a hydrido or C<sub>1</sub>-C<sub>4</sub> alkyl group;

R<sup>6</sup> is selected from the group consisting of a hydrido, cycloalkyl, heterocycloalkyl, aryl,

10 heteroaryl, aralkyl, heteroaralkyl, cycloalkylalkyl, heterocycloalkylalkyl, alkoxyalkyl, alkylthioalkyl group, and a -(CH<sub>2</sub>)<sub>x</sub>-NR<sup>11</sup>R<sup>12</sup> group wherein x is an integer from zero to 6, wherein an aryl or heteroaryl group of R<sup>6</sup> is optionally substituted with one or more 15 substituents independently selected from the group consisting of a halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, nitro, cyano, hydroxy, carboxy, hydroxycarbonylalkyl, -(CH<sub>2</sub>)<sub>x</sub>-NR<sup>11</sup>R<sup>12</sup>, wherein x is an integer from zero to 6, trifluoromethyl, alkoxycarbonyl, aminocarbonyl, 20 thio, alkylsulfonyl, carbonylamino, aminosulfonyl, alkylsulfonamino, alkoxyalkyl, cycloalkyloxy, alkylthioalkyl and alkylthio group;

or R<sup>5</sup> and R<sup>6</sup> together with the atom chain to which they are bonded form a 5- to 7-membered 25 a cyclic amide or imide that is substituted or unsubstituted;

R<sup>7</sup> is selected from the group consisting of R<sup>6</sup> and alkyl; or R<sup>5</sup> and R<sup>7</sup> together with the atom chain to which they are bonded form a 5- to 7-membered a

cyclic sulfonamide that is substituted or unsubstituted;

R<sup>8</sup> and R<sup>9</sup> are independently selected from the group consisting of R<sup>6</sup> and alkyl, or R<sup>8</sup> and R<sup>9</sup> together with the depicted nitrogen atom form a 5- to 7-membered ring containing zero or one heteroatom that is oxygen, nitrogen or sulfur;

R<sup>11</sup> and R<sup>12</sup> are independently selected from the group consisting of a hydrido, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, alkanoyl, aralkanoyl, and heteroaralkanoyl group, or R<sup>11</sup> and R<sup>12</sup> taken together form a 5 to 8-membered heterocyclo or heteroaryl ring; and

R<sup>13</sup> is a hydrido or C<sub>1</sub>-C<sub>6</sub> alkyl group.

15

23. The process according to claim 22 wherein n is 2.


24. The process according to claim 22  
20 wherein R<sup>1</sup> is arylene.

25. The process according to claim 22  
wherein W is -NR<sup>5</sup>COR<sup>6</sup>.

25 26. The process according to claim 22  
wherein W is -NR<sup>5</sup>S(O)<sub>z</sub>R<sup>7</sup>.


27. The process according to claim 22  
wherein said compound corresponds in structure to  
30 formula III

-213-



wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup> and R<sup>13</sup> are  
5 defined above.

28. The process according to claim 22  
wherein said compound corresponds in structure to  
formula V



10

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>7</sup> and R<sup>13</sup> are  
defined above.

15

29. The process according to claim 22  
wherein said compound is administered a plurality of  
times.

20

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/04299

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07D 413/12, 265/30; A61K 31/535, 31/44

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 5,646,167 A (MACPHERSON et al.) 08 July 1997, entire document.	1-29
Y	US 5,506,242 A (MACPHERSON et al.) 09 April 1996, entire document.	1-29
Y	US 5,552,419 A (MACPHERSON et al.) 03 September 1996, entire document.	1-29
A	US 4,337,197 A (GORDON et al.) 29 June 1982, entire document.	1-29
X	EP 0 757 984 A1 (ONO PHARMACEUTICAL CO., LTD.) 12 February 1997, entire document.	1-29

 Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 MAY 1998

Date of mailing of the international search report

18 JUN 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer

MATTHEW V. GRUMBLING

Telephone No. (703) 308-1235



**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US98/04299**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	WO 97/27174 A1 (SHIONOGI & CO., LTD.) 31 July 1997, entire document.	1-29
A	WO 96/26223 A1 (BRITISH BIOTECH PHARMACEUTICALS LIMITED) 29 August 1996, entire document.	1-29
A	WO 95/35276 A1 (BRITISH BIOTECH PHARMACEUTICALS LIMITED) 28 December 1995, entire document.	1-29
A, P	WO 98/07742 A1 (ZENECA LIMITED) 26 February 1998, entire document.	1-29

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US98/04299

**A. CLASSIFICATION OF SUBJECT MATTER:**  
US CL :

544/85, 133 146, 130, 131, 137, 141, 148; 546/247, 233, 234, 236, 237, 265; 548/204; 514/231.5, 231.8, 237.2, 316, 318, 236, 342, 343, 365

**B. FIELDS SEARCHED**

Minimum documentation searched  
Classification System: U.S.

544/85, 133 146, 130, 131, 137, 141, 148; 546/247, 233, 234, 236, 237, 265; 548/204; 514/231.5, 231.8, 237.2, 316, 318, 236, 342, 343, 365

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**